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ABSTRACT 
 
Research in the pharmaceutical field involves investigation of a new drug, delivery route, 
a delivery system, a technology to design the delivery system, or a combination thereof. 
Scientists have explored several delivery routes such as oral, pulmonary, nasal, injection/implant, 
transdermal/dermal, transmucosal etc. for their potential to transport a variety of small and large 
drug molecules. In the present research work, oral route, a widely accepted route of 
administration, for the delivery of products with a major market share, has been considered for 
the delivery of poorly soluble actives. The use of appropriate carrier matrices (polymers) and 
excipients help in incorporating these drugs and developing a dosage form/drug delivery system 
with desired properties. The oral delivery systems are most popular, convenient for 
administration, and mainly include conventional solid dosage forms such as pellets, tablets, and/ 
or milled material filled in capsules. Since most of the actives studied under current research 
have low aqueous solubility, it was necessary to utilize a novel technology such as hot melt 
extrusion (HME) in combination with hydrophilic polymers to obtain tailored drug release.   
Over recent years HME technology has found widespread application as a viable drug 
delivery option in the drug development process. Some of the HME applications include taste 
masking, solid-state stability enhancement, solubility enhancement etc. Solubility enhancement 
in the HME process occurs through the dispersion of a poorly soluble drug in a polymeric carrier 
matrix essentially forming a solid dispersion. While this technology can help in producing 
amorphous or crystalline solid dispersions depending upon several factors, solubility 
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enhancement applications are centered on generating amorphous dispersions, primarily because 
of the free energy benefits they offer. Amorphous solid dispersions result when melt extruded 
drug-polymer is cooled at a rate that does not allow the drug to recrystallize, or processed at 
temperatures where drug melts but remains immiscible with the carrier. Such processing results 
in kinetic entrapment of the drug in its amorphous state. These dispersions also provide 
maximum specific surface area and higher saturation solubility, which ultimately increase drug 
solubility. Although these types of systems exhibit increased rate of dissolution due to high 
thermodynamic activity, they have a potential to revert to the more stable crystalline form. 
Thorough understanding of the physicochemical properties of amorphous solid dispersions and 
their corresponding in vivo behavior is required for the realization of their true potential in the 
pharmaceutical industry.  
In the research projects outlined in this dissertation, the focus has been to characterize the 
different hydrophilic polymeric extrudates produced utilizing HME technology, and emphasize 
their pharmaceutical applications. HME, in conjunction with suitable polymers, has been 
demonstrated as a viable approach to develop a novel pellet dosage form with potential abuse 
deterrent properties. In addition, its application for solubility enhancement aims at generating 
amorphous solid dispersions utilizing novel hydrophilic polymers, followed by the in-depth 
characterization of the produced melt extrudates. Moreover, the effect of various formulation 
variables and process parameters has also been investigated. This underlying research also 
facilitates the development of a wide-ranging stable solid oral dosage forms with modulated drug 
release. 
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The key objectives of the chapters in the dissertation are: (1) To develop an abuse-
deterrent (AD) platform technology in the formulation development utilizing HME technique; 
(2) To investigate the effect of process variables and formulation factors on characteristics of hot 
melt extrudates containing hydrophilic vinylpyrrolidone/vinyl acetate copolymer (Kollidon
® 
VA 
64); (3) To investigate the feasibility of producing stable drug-loaded Soluplus
®
 extrudates 
utilizing HME technology, and to study the influence of formulation and processing parameters 
such as drug-load and heating duration, respectively, on the drug-polymer miscibility as well as 
the release from melt extrudates; (4) To explore the feasibility of producing soluble Soluplus
®
-
Curcumin extrudates utilizing HME technology, including the drug-polymer miscibility studies, 
and the influence of surfactants on dissolution rate of this poorly water-soluble model drug.  
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CHAPTER - 1 
Hot Melt Extrusion: A Promising Technique to Produce a Novel Abuse-Deterrent/Tamper-
Resistant Formulation 
1.1.Introduction  
In recent years, prescription drug abuse has been identified as source of rapidly growing 
concern in the United States. Of all the available drugs, Opioids, CNS depressants and stimulants 
are the three most established drug classes that are abused, next to marijuana (1). Pain, being a 
potentially debilitating symptom associated with a variety of chronic medical conditions, has 
necessitated the application of numerous opioids, which have a high potential for abuse. The 
number of prescriptions for these drugs has also increased considerably over the past two 
decades (2). Moreover, as per one of the national surveys, more focus on the non-medical use of 
these opioids has been noticed in all of the different age groups, teenagers being a major 
constituent amongst those abusers (3, 4). In addition, the number of emergency visits as well as 
the death rates due to overdose of these medications has increased dramatically over the past few 
years (5). These drugs, being reasonably accessible to the population, have been largely misused 
or abused via physical or chemical manipulation in order to obtain high drug concentration in the 
body to produce euphoric effects, or a significant “high”.   
The majority of the opioids/ controlled substances that have shown potential for abuse are 
available in the form of immediate release (IR) and extended release (ER) tablets and capsule 
dosage forms, trans-dermal patches, trans-mucosal lozenges etc. The consumption of more 
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number of IR units via oral route results in higher concentrations of the drug in the systemic 
circulation, producing the desired “high” (6). In addition, there has been a marked interest in 
manipulating the ER dosage forms due to the large dose of the drug per unit dosage form (7). 
Apart from the oral route, alternative delivery routes have been explored by the abusers to 
achieve a similar psychological feel in a short period or with a limited amount of material in 
hand (8). Since these conventional formulations are not hard enough to resist crushing, the 
obtained powder-like fine material is easily snorted via nasal route. In the same scenario, if the 
active is highly soluble in the aqueous medium, it could be extracted in a small volume and 
injected directly into the blood stream to get an instantaneous “high.” Some of the other drugs 
with higher vapor pressures are abused or misused by smoking or volatilization (9). An 
epidemiologic study conducted on the subjects who were addicted to Oxycontin (Oxycodone 
HCl), have reported that majority of the users have started taking the drugs orally, but over the 
time have advanced to administering the API through different routes: 62% reported snorting, 
26% through injecting, and only 14% by oral route (10). 
Due to this alarming issue, the recent interest of several pharmaceutical industries has 
been shifted towards developing a platform technology, which either prevents or minimizes the 
abuse of, or tampering with, the prescription opioids. Currently, there are surprisingly few 
formulations that are either under development or commercially available in the United States 
that demonstrate such properties (11). Some of the marketed products that are currently approved 
by United States Food and Drug Administration (FDA) are Oxycontin
®
 OP ER tablets, Oxecta 
IR tablets, Suboxone sublingual tablets, Nucynta ER tablets, and Opana ER tablets. These 
emerging opioid containing formulations were produced by novel approaches such as 
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incorporation of gelling agents, nasal irritants, antagonists etc., in the formulations. Thus, they 
are not only designed to discourage the abusers by reducing the risk of misuse and/or abuse, but 
are also dually beneficial to physicians in meeting their goals of maximizing pain relief in 
afflicted populations. However, none of these formulations can guarantee an absolute abuse 
deterrence/tamper proof. In addition, the majority of these formulations have been produced via 
conventional methodologies involving several processing steps such as wet/dry granulation, 
blending, compression, curing, coating, etc., which adds longer time and higher cost to the 
development process. 
Although research in this particular area has gained enormous attention due to the 
pressure from the law makers and the FDA, there is not much literature published/available, 
especially on the TR formulations developed utilizing novel hot melt extrusion (HME) 
technology. In a recent study by Bartholomaeus et al. the authors produced an ER opioid 
formulation with crush-resistant features using a combination of a planetary-gear extruder and a 
tablet press on a laboratory scale, which involved few processing steps (12). However, their 
primary objective was to stabilize the formulation and be bioequivalent to the marketed ER 
formulation. In addition, the rationale for their formulation selection does not involve DOE and 
necessitates further discussion.  
The objective of this current research is two-fold. Firstly, utilizing a DOE approach and 
employing HME processing in identifying and producing an optimal formulation. Secondly, to 
produce TR formulations that is more resistant to crushing/grinding/milling (to avoid 
insufflation), and to minimize the drug extraction (to avoid abuse via injection). HME is a novel 
and viable technique that has been effectively utilized in the pharmaceutical industry to improve 
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the bioavailability of the actives, especially those having low aqueous solubility, by formation of 
molecular dispersions (13-15). This technique is also time-efficient and cost-effective, due to the 
involvement of fewer processing steps, and utilization of limited excipients. In this study, we 
have made a sincere attempt to demonstrate the capability of single-step HME technology in 
producing a TR formulation utilizing appropriate commonly used excipients (16, 17). It should 
be noted that the terms ‘TR’ and ‘AD’ may be used interchangeably throughout this paper. 
1.2.Materials and Methods 
1.2.1. Materials 
Lidocaine HCl (LID) and Vitamin E Succinate (VES) were purchased from spectrum chemicals 
(Decatur, AL, USA). PolyOx™ WSR 301 (PEO-301), and PolyOx™ N80 (PEO-N80) were 
kindly gifted from Colorcon (West point, PA). Benecel™ K4M (HPMC K4M), and Benecel™ 
K15M (HPMC K15M) were kindly gifted from Ashland Inc. (Wilmington, DE). Eudragit
®
 
RSPO (EUD) and Carbopol 71G (CBP) were kindly gifted by Evonik (Piscataway, NJ), and 
Lubrizol (Cleveland, Ohio), respectively. Dibasic potassium phosphate and tribasic sodium 
phosphate were purchased from sigma-Aldrich (St. Louis, MO). High performance liquid 
chromatography (HPLC) grade water was freshly prepared in the laboratory by Nanopure 
systems (Barnstead, Dubuque, IA, USA). All solvents utilized in the study were of analytical 
grade and obtained from Fisher Scientific (Fair Lawn, NJ, USA). 
1.2.2. Analytical Method 
An in-house reverse phase high performance liquid chromatography (HPLC) based analytical 
method was developed for the determination/quantification of LID. This method was validated 
according to ICH and FDA guidelines for chromatographic methods. An HPLC equipped with a 
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UV detector, Waters Symmetry shield 5μ C18 column (250×4.6 mm), and an isocratic mode of 
elution with the mobile phase consisting of 20mM ammonium acetate with 30mM TFA, 
acetonitrile, and methanol (70:10:20) at a flow rate of 1.2 mL/min were employed to quantify the 
drug at a wavelength (λmax) of 254 nm. The acquired data was processed using Empower 2 
build 2154 software (Waters Inc., Mount Holly, NJ, USA). 
1.2.3. Preparation of Physical Mixtures/ Blends 
Prior to extrusion, the required materials were sieved through a USP # 30 (600µM) mesh, 
accurately weighed, and transferred to a twin-shell V-blender (The Patterson-Kelly co., Inc. East 
Stroudsburg, PA). The materials were then mixed at 25rpm for 10 minutes in the V-blender to 
obtain a homogeneous blend. 
1.2.4. Preparation of Hot Melt Extrudates 
1.2.4.1.HME: Initial Screening 
In order to identify a suitable carrier matrix to produce an AD/TR formulation, different 
polymers such as HPMC K4M, HPMC K15M, PEO-301, and EUD were evaluated for 
extrudability at barrel temperatures ranging from 110°C-180°C and a screw speed of 50 rpm in a 
twin-screw compounder (MiniLab II HAAKE Rheomex CTW5, ThermoFisher Scientific). The 
polymeric matrices selected from those tested, (i.e. PEO-301 & EUD, and their blends mixed in 
ratios of 1:1, 2:1, and 1:2 PEO-301 and EUD respectively) were extruded with LID at barrel 
temperatures ranging from 110˚C-130˚C and a screw speed of 50 rpm utilizing a lab scale twin-
screw Hot Melt extruder (Prism 16mm EuroLab, Thermo Fisher Scientific) with 3mm diameter 
circular die. All of the extrudates contained 10% w/w VES as a processing aid and 20% w/w 
LID. The obtained extrudates were cut to a length of 3mm using a bench-top pelletizer (Thermo 
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Fisher Scientific) and stored appropriately until further testing. 
1.2.4.2.HME: Box-Behnken DOE  
Based on the results from the initial screening, PEO-301 was chosen as the carrier matrix, while 
HPMC K15M and CBP were employed as gelling agents; each of these were designated as a 
formulation factor. Box-Behnken design (Table 1-1) was used to determine the effects of the 
three formulation factors, each at three levels, on TR characteristics of the melt-extruded pellets. 
A response surface methodology was utilized to identify the optimized formulation. A total of 14 
formulations, including two center points, generated by the design were extruded at temperatures 
ranging from 110˚C-130˚C and a screw speed of 50 rpm using a twin-screw hot melt extruder 
(Prism 16mm Eurolab ThermoFisher Scientific). The final extrudates were then cut to 3mm in 
length using a bench-top pelletizer (ThermoFisher Scientific) and stored until further testing. 
Table 1-1: Box-Behnken Design for the Three Formulation Factors (PEO-301; HPMC 
K15M; and CBP) Under Study 
Std Order Run Order Pt Type Blocks PEO-301 
HPMC 
K15M 
CBP 
2 1 2 1 40 10 6 
13 2 0 1 30 15 6 
5 3 2 1 20 15 2 
8 4 2 1 40 15 10 
14 5 0 1 30 15 6 
10 6 2 1 30 20 2 
6 7 2 1 40 15 2 
12 8 2 1 30 20 10 
1 9 2 1 20 10 6 
11 10 2 1 30 10 10 
9 11 2 1 30 10 2 
3 12 2 1 20 20 6 
7 13 2 1 20 15 10 
4 14 2 1 40 20 6 
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The experimental design and data analysis were conducted using Minitab
®
 15.0. The current 
response surface methodology DOE was analyzed using multiple regression statistics. A full 
quadratic model was fitted to the collected responses, and ‘P’ values for each of the factors were 
used to determine their significance. Highest order, most insignificant terms were sequentially 
removed until the significant factors were identified. Residual analysis was performed on the 
final reduced model, and the developed model was validated by executing and analyzing a 
confirmation run.  
1.2.5. Weight Variation 
Twenty pellets from a 100g batch were randomly selected from each of the DOE formulations 
and weighed using a Sartorius lab scale digital balance. The values were recorded, and the mean 
± standard deviation (SD) was calculated. 
1.2.6. Hardness and Friability Testing 
The diametric compression strength testing was performed on ten randomly picked pellets per 
formulation using the Varian tester, and the hardness values were recorded. 
The friability testing was performed on a sample of approximately 6.6g of extruded pellets 
utilizing a Varian friabilator. Pre-weighed pellets were placed in a friabilator and rotated at a 
speed of 25rpm for 4min. The pellets were then de-dusted, reweighed, and percentage weight 
loss (friability) was calculated for all of the DOE formulations. 
1.2.7. Fine particle reduction 
The obtained pellets equivalent to 200mg of weight from each of these formulations were 
evaluated for particle size reduction. The pellets were initially subjected to a low-shear grinding 
in a mortar and pestle for about 5min, followed by milling using a coffee grinder for an 
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additional 5min. The obtained particles (n=3) were passed through a USP # 100 (150 µm) mesh, 
and the fraction retained on the sieve was recorded.  
1.2.8. Drug Extraction in Water 
200mg of extruded pellets (equivalent to 40mg of LID) were added to 5ml of de-ionized water in 
a 20mL scintillation vial. Each of these formulations was vortexed for 2 minutes and kept aside 
for 30 minutes. At the end point, the samples were further mixed, and an aliquot of 1mL was 
collected, further diluted with methanol, filtered using 0.2 µm, 13mm PTFE membrane filters 
(Whatman, Piscataway, NJ). These solutions were analyzed using an HPLC at a wavelength of 
254 nm. The test was performed in triplicate and the mean ± SD were recorded. Additionally, 
these resultant solutions/dispersions have been qualitatively assessed for an increase in the 
viscosity or by visual observation for gel formation.   
1.2.9. Drug Extraction in Alcohol 
The extruded pellets (200mg) with a dose containing approximately 40mg drug were taken and 
dispersed in 60mL of 50% v/v absolute alcohol (simulating one large shot of whiskey). Each of 
these formulations was vortexed for 2 minutes and kept aside for 30 minutes. At the end point, 
the samples were further mixed, and an aliquot of 1mL was collected, diluted with methanol, 
filtered using a 0.2 µm, 13mm PTFE membrane filters (Whatman, Piscataway, NJ), and analyzed 
utilizing an HPLC at a wavelength of 254 nm. The test was performed in triplicate and the mean 
± SD were recorded. 
1.2.10. Drug Release Studies 
The in vitro dissolution studies were carried out on the extruded pellets containing PEO, EUD, 
and their blends as polymeric matrices with approximately 40mg of LID. The pellets are 
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weighed accurately and filled in size#1 gelatin capsules. Dissolution testing (USP XXXI, 
Apparatus II) was performed utilizing a Hanson SR8-plus™ dissolution test station (Hanson 
Research Corporation, Chatsworth, CA) operated at 100-rpm paddle speed. The dissolution 
medium consisted of 750mL of 0.1N hydrochloric acid (pH 1.2), preheated to 37°C. After 2hrs, 
250mL of 0.2M tribasic sodium phosphate was added to the existing medium in the dissolution 
vessel and the pH of the entire medium in the dissolution vessel was adjusted to pH 6.8 by 
adding either 2N HCl or NaOH. An aliquot of 1.5mL was collected at pre-determined time 
intervals, filtered, and analyzed using an HPLC at a λmax of 254nm. Drug concentrations were 
calculated from a standard calibration plot and expressed as cumulative percentage drug 
dissolved. The release studies were also performed in triplicate and the mean values were 
compared. 
1.3. Results  
1.3.1. Analytical Method 
The validation of the HPLC method employed in this study was carried out as per the ICH and 
FDA guidelines for chromatographic methods. The linear calibration range for the detection of 
LID was found to be 5-200 μg/mL, with a coefficient of determination (R2) of 0.999. The limit of 
detection and quantitation for the drug were 0.3 and 1.0 µg respectively, and the retention time 
for LID was 8.9 minutes. The percentage relative standard deviation (RSD) within replicates 
(n=3) was less than 2.0%, which demonstrates the reproducibility of the method. Precision was 
tested by injecting a single drug concentration (20μg/mL) 10 times, and the peak area was 
recorded and evaluated. A precision of less than 1.0% of RSD was observed.  
1.3.2.  Weight Variation, Hardness and Friability Testing 
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For all of the formulations, the weight and length of the pellets were within 28mg±10% and 
3mm±5%, respectively. The hardness of the extruded pellets increased as the concentration of 
PEO-301 in the extruded pellets increased. This seemed especially true when the concentration 
of PEO-301 exceeded 50% of the total polymer weight. Moreover, the pellets made of pure 
PEO-301 could not be broken, but could only be deformed by the apparatus. A maximum 
hardness of 35kP was displayed on the instrument. This indicates a plastic behavior as a result of 
thermoplastic nature of the PEO-301 (Figure 1-1). Friability values were less than 0.1% in all of 
the DOE batches produced.  
 
Note: The extrudates prepared from PEO-301 (pure PolyOx™ WSR 301) could only be 
deformed, but not broken during the hardness evaluation. 
Figure 1-1:  Hardness Evaluation of the Preliminary Melt-Extruded Pellet Formulations 
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1.3.3. Fine particle reduction 
All of the particles obtained from grinding the extruded pellets in a mortar and pestle, followed 
by milling in a coffee grinder, were completely retained on the USP # 100 mesh screen (>150µ). 
1.3.4. Drug Extraction in Water 
The intact pellet formulation with pure PEO-301 had 27.4% of the drug extracted in water 
(approximately 11mg out of 40mg of LID) over 30 minutes, whereas all of the other 
formulations have shown higher drug extraction (>50%) over the same period (data not 
presented). The formulation with pure PEO-301 visually demonstrated a superior gel formation 
when compared to the other formulations. 
1.3.5. Drug Extraction in Alcohol 
The observed drug extraction in alcohol (ethanol) was only 21.3% from the intact pellets 
containing pure/unblended PEO-301 in comparison to those made with pure EUD, which was 
approximately 50% of LID loading. The percentages of drug extracted in alcohol from all of the 
other intact pellet formulations were found to be between that of the pure polymer compositions. 
In addition, milled pellets exhibited significantly higher drug extraction compared to the intact 
pellets as depicted in Figure 1-2. 
 12 
 
   The pellets made of PEO-301 could not be milled into fine powder. Hence, this sample was not 
tested for drug extraction in alcohol from the Hot Melt extruded pellets. 
Figure 1-2:  Drug Extraction in Alcohol from the Preliminary Melt-Extruded Pellet 
Formulations 
1.3.6. Drug Release Studies 
All of the extruded formulations, irrespective of their polymeric compositions (varying PEO: 
EUD ratios), have demonstrated similarity factor values (f2) of greater than 50. The pellets 
composed of PEO-301 alone with 20% LID served as the reference (Figure 1-3). 
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Figure 1-3:  Drug Release from the Preliminary Melt-Extruded Pellet Formulations 
1.4. Discussion 
Due to controlled and restricted access to opioids, an active with high water and alcohol 
solubility (LID) was chosen as a model drug in the current study. Different carrier matrices such 
as HPMC K4M, HPMC K15M, PEO-301, and EUD were initially screened to identify suitable 
carriers that exhibit AD/TR properties. When attempting to extrude neat polymers at 90% w/w 
polymer level, formulations containing HPMC could not be extruded even at temperatures as 
high as 180°C. Irrespective of its molecular weight, HPMC could not be plasticized under the 
employed extrusion conditions, and consequently was not pursued further as a carrier matrix. On 
the other hand, PEO-301 and EUD were easily extruded at a much lower temperature range of 
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125-140°C. The next level of screening involved studying the effects of chosen polymeric 
carriers (PEO-301 and EUD) and their combinations at three different ratios to produce 
formulations with AD/TR features. All of these five formulations could be extruded relatively 
easily, and without incident. These formulations were subjected to hardness, crushing, extraction 
and dissolution testing to choose the best carrier among those tested, that is, the one with the 
most favorable AD/TR properties.  
Snorting/insufflation is one of the most convenient and predominant modes of drug 
abuse, where the tablet formulations are finely crushed and inhaled or “snorted” via nasal route 
to get rapid onset of action. When inhaled intra-nasally, drugs could reach both the brain (by-
passing the blood-brain barrier), and the systemic circulation (by-passing intestinal and hepatic 
metabolism). Targeting the drugs to the brain would be the most effective approach to get an 
instant “high” if the particles could get deposited in the olfactory region (required particle size 
<5 µm), which facilitates the drug’s entrance into the cerebrospinal space (18). However, this 
small particle size could also result in the drug deposition in the lower airways. Conventional 
nasal formulations, on the other hand, maintain a particle size of 20-30 µm to facilitate their 
permeation across the highly vascularized nasal mucosal epithelium (18). However, because of 
the low volume availability in the nasal environment, the rate-limiting step for drug absorption 
would be drug dissolution. Therefore, to produce a formulation with TR properties, it is required 
to alter the formulation such that the particle size could not be minimized to an appreciable 
extent. This results in a decreased surface area and ensures slower drug dissolution in the 
available low volume nasal cavity. It has been demonstrated in this study that all of the pellet 
formulations obtained from either pure EUD or its combination with PEO-301 could be broken, 
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but not reduced into very fine particles as was attempted by the milling process in a coffee 
grinder (Figure 1-4).  
 
Figure 1-4:  Visual Comparison of Different HME Pellet Formulations before and after 
Particle Size Reduction   
Another route of abuse that has gained considerable attention, and is highly favored 
among abusers, is through extraction of the drug into aqueous solvent and injecting it directly 
into the blood stream. To prevent this, a TR formulation should be able to gel sufficiently when 
in contact with the aqueous media in order to minimize drug extraction. All of the extruded pellet 
formulations, except the one containing pure EUD, exhibited a reasonable gelling tendency in 
water. Moreover, the formulation extruded with pure PEO-301 has demonstrated increased 
swelling and produced a superior viscous gel relative to the other formulations. Although the 
high molecular weight PEO-301 does hydrate and subsequently forms an extraction preventative 
gel layer, polymer hydration tends to occur somewhat more slowly than small molecule 
dissolution. The coupling of these two events could have resulted in the drug’s escape prior to 
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the gel formation event. On the other hand, EUD being a copolymer of ethyl acrylate and methyl 
methacrylate, and having a low content of the methacrylic acid ester with a quaternary 
ammonium group, it is less permeable and practically insoluble in water and might have 
undergone erosion. Hence, as the EUD concentration in the formulation increased, the drug 
extraction from the intact pellets might also have increased due to both high drug solubility 
leading to diffusion through any formed channels, and lack of EUD gelling in the aqueous phase. 
Apart from the aqueous media, extraction studies were also carried out in hydro-alcoholic 
solutions. This increased drug extraction from EUD pellets was attributed to the higher solubility 
of both the EUD polymer and drug in alcohol. Apart from testing the whole pellets, all of the 
extrudates were subjected to milling and the milled portions were also exposed to alcohol for 
LID extraction. As expected, due to an increase in surface area as a result of milling, all of these 
formulations under investigation have shown much greater drug release in alcohol (60-90%) 
when compared to the intact pellets (21-50%). The percent drug extracted between intact and 
milled pellets for all of the tested formulations was statistically significantly different (p<0.05). 
However, the drug extraction from the milled PEO-301 pellets could not be performed as the 
pure PEO compacts were very plastic in nature and, as previously mentioned, very difficult to 
crush. 
 The obtained dissolution data was fitted to different release models, and the drug release 
mechanism from all of these formulations was established using the Krosmeyer-Peppas model. 
The high coefficients of determination (R
2
) values were observed when plotted as per the 
Higuchi equation, which indicates that, the regression line fits the data well. Additionally, the 
calculated ‘n’ values for all of these five preliminary formulations were in the range of 0.28-0.37, 
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which indicates that the drug’s release is mainly by fickian diffusion. 
PEO-301, being a hydrophilic polymer, demonstrates rapid hydration and swelling of the 
polymer when in contact with the aqueous media resulting in the formation of a uniform gel 
layer on the surface of the matrix. Since the model drug under investigation is highly water-
soluble, it quickly gets dissolved in the media and diffuses out through the channels formed due 
to polymer swelling (19). However, the molecular weight of the polymer under discussion, PEO-
301, is relatively high (4 million), resulting in a slower gel erosion and a prolonged drug release 
behavior, which translates to reduced extractability. On the other hand, although the EUD 
matrices hydrate to a lesser extent, the drug release follows a similar mechanism of diffusion. 
This could be attributed to the high aqueous solubility of the LID that diffuses through the 
channels formed due to EUD erosion, or dissolution of other soluble formulation components. 
The study results were in accordance with the previously reported data in the literature (20).  
Based on the preliminary results obtained from the above studies, it has been concluded 
that the pure PEO-301 extrudates exhibited the most suitable properties as an AD/TR carrier 
matrix when processed by HME. However, these pellets need further improvement to minimize 
the drug’s extraction in aqueous media, thereby preventing intravenous drug abuse. In order to 
improve the formulation further, excipients such as CBP and HPMC K15M were employed as 
gelling agents, and Vitamin E Succinate (VES) was used a processing aid in all of the 
formulations. Both of these polymers, each at three different levels, were studied as gelling 
agents to increase the viscosity of the formulation when in contact with water. 
CBP was studied in a broad range of concentrations (2-10% w/w). In general, if the 
concentration of CBP in the formulation is beyond 3%, it could potentially exhibit pH dependent 
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drug release, which is not desirable. However, the grade of CBP chosen is a granular form, and 
requires a high concentration (~10% w/w or higher) in the formulation to demonstrate gelling 
and pH dependency. For CBP to act as a gelling agent, an alkaline environment is required to 
ionize the polymeric chains and induce swelling for gel formation. Therefore, K2HPO4 was 
added as a buffering agent in the formulation. Furthermore, researchers have utilized HPMC up 
to 30% w/w in controlled release tablet formulations to provide sufficient gelling. However, 
when used at high levels, there is a potential for the development of a brittle formulation that 
could be crushed easily and compromise the insufflation inhibiting feature. When a minimal 
amount of HPMC is used, there is a possibility of insufficient gel formation in water leading to 
enhance drug extraction. As our primary intent was to improve the extraction in water (learning 
from the preliminary experiments), 10-20% w/w range was assumed to be reasonable to study. 
With several ingredients present in the formulation, a DOE was performed to optimize the levels 
of PEO-301, HPMC K15M and CBP to produce a formulation with better TR/AD features 
keeping all of the other components unchanged except for PEO-N80, which was used as filler. 
The base formulation composition utilized for DOE and its excipient functionality is presented in 
Table 1-2. 
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Table 1-2: Composition and Functionality of Hot Melt Extruded Base Pellet Formulation 
Utilized in Design of Experiments  
Formulation Components Concentration (% w/w) Functionality 
Lidocaine HCl (LID) 20 Active 
PEO-301 20 – 40 Gelling Polymeric Matrix 
HPMC K15M 10 – 20 Gelling Polymeric Matrix 
Carbopol 71G (CBP) 2 – 10 Gelling Agent 
Vitamin E Succinate 10 Process Aid 
K2HPO4 1 Base/Gel Promoter 
PEO-N80 3 – 33 Polymeric Filler 
 
 All of the extruded formulations produced under DOE were evaluated for various TR 
tests and the obtained results were considered responses for optimization. The TR tests 
performed were: (a) hardness testing using a Varian hardness tester; (b) fine particle reduction 
using a mortar & pestle and a coffee grinder, followed by passing the milled extrudates through a 
100 mesh screen; (c) extraction of the active pharmaceutical ingredient (API) in water; and (d) 
extraction of the API in 60mL of 50% v/v absolute ethanol. 
A total of 14 formulations produced under the Box-Behnken design, including two center 
points, were easily extruded at the employed conditions. This design is a more efficient DOE 
compared to a full factorial or a central composite design with an equal number of factors. The 
Box-Behnken design uses edge midpoints; the design is run at a condition halfway between two 
crners rather than at a corner. Moreover, this design does not use axial points. Hence, all of the 
design runs will be within the initial design space. This feature is useful when it is necessary to 
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ensure that all design runs are in defined or “safe” operating space. 
Hardness testing revealed that all of the produced formulations were plastic in nature and 
deformed. A maximum hardness value of 35kP was recorded on the instrument. None of the 
pellets subjected to testing could be broken. LID pellet formulations demonstrated good post-
processing drug content (approximately 99.0% and a relative standard deviation of 2.0%). In 
addition, a low-shear pulverization using mortar & pestle, followed by milling in a coffee grinder 
generated particles with reduced size in all of the DOE formulations. However, none of these 
formulations passed through mesh # 100 when subjected to sieve analysis, and the particle size 
of all of the milled portions were larger than 150µ, which is indicative of the formulations’ 
resistance to snorting/insufflation. As mentioned earlier, the larger the particle size, the smaller 
the surface area, which could lead to a relatively slower dissolution and lower absorption across 
the nasal environment.  
All of the formulations exhibited an appreciable gelling tendency in water with only 8-
12% of drug being extracted. Good gelling behavior in water is attributed to the water uptake 
potential of the employed hydrophilic polymers present in the formulation and their ionizable 
groups, due to the micro-environmental pH, resulting in an increase in the viscosity of the 
aqueous medium. Studies in the literature have reported that HPMC in combination with CBP 
demonstrated a synergistic effect with a stronger cross linking between the polymers leading to 
the formation of a more firm gel structure because of the hydrogen bonding between the anionic 
CBP and the HPMC. Additionally, interaction between non-ionic polymers has also been well 
established in the literature. Some reports have mentioned that PEO in combination with HPMC 
might be favorable when slower initial release is required from the matrices. Both PEO and 
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HPMC, being hydrophilic and non-ionic polymers, are dually advantageous in that they can 
facilitate a faster hydration of PEO-301, and could also result in the formation of a stronger gel 
layer. This ultimately results in minimizing the drug diffusion from the swollen matrix while 
simultaneously decreasing the erosion rate of the formed gel layer (21). Similar behavior was 
also reported with HPMC in the presence of non-ionic hydrophilic polymer, hydroxylpropyl 
cellulose (HPC).  
When analyzing the percentage of the API extracted in water, the level of HPMC K15M 
was the only factor that demonstrated a significant influence on the response (P<0.05). The R-Sq 
(adjusted) value in the final reduced model indicated that the model explained 35% of the data 
variability (Figure 1-5). In addition, the P value for ‘Lack-of-Fit’ was found to be 0.136 
(P>0.05). Therefore, the null hypothesis was accepted i.e., the model developed is not different 
from the proper fitting model. The reduced final model for this response can be provided as 
follows:  
  Percentage API extracted in water = 8.085 + 0.172 (HPMC)..........Equation 1 
The drug extraction in alcohol was another response that ranged from 17-45%, amongst 
different formulations tested. Similar results were observed in a study conducted by Robert et al. 
who studied the release of aspirin from HPMC matrix in hydro-alcoholic media (22). The 
authors noticed an initial sudden burst release of the drug without causing any dose dumping, 
which was attributed to the delayed hydration of HPMC in the alcoholic medium. Therefore, in 
the present study both PEO and HPMC being insoluble in alcohol, high drug extraction in 
alcohol was accounted for by the high solubility of LID as well as the delayed hydration of the 
HPMC polymeric matrix in the presence of ethanol. 
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Figure 1-5: Response Surface Regression after Model Reduction Obtained Using “Percent 
API Extracted in Water” as a Response 
‘Percentage API extracted in alcohol’ was also significantly influenced (P<0.05) by the 
level of HPMC K15M employed in the formulation. When the obtained data was fitted to the 
model, the R-Sq (adjusted) value in the final reduced model indicated that the model explained 
34% of the data variability (Figure 1-6). In addition, the P value for ‘Lack-of-Fit’ was found to 
be 0.377 (P>0.05). Hence, the null hypothesis was accepted i.e., the model developed is not 
different from the proper fitting model. The reduced final model for this response can be 
provided as follows:  
           Percentage API extracted in alcohol = 6.787 + 1.343 (HPMC)……….Equation 2 
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Figure 1-6: Response Surface Regression after Model Reduction Obtained Using “Percent 
API Extracted in Alcohol” as a Response 
The standardized residual plots (Figures 1-7A and 1-7B) of the final reduced models for 
the responses ‘percentage API extracted in water’ and ‘percentage API extracted in alcohol’ 
meet all of the basic assumptions of a good model fit. The figures indicate that the residuals are 
normally distributed around approximately the mean of zero. Moreover, the residuals are 
homoscedastic, also known as homogeneity of variance (residuals have constant variability and 
are independent of fitted value), and do not show any trending (independent of observation 
order). Response optimization plots (Figure 1-8A and 1-8B) indicated that lower extraction of 
Response Surface Regression: Alcohol Gelling versus HPMC  
 
Final reduced Model: The analysis was done using uncoded units. 
 
Estimated Regression Coefficients for Alcohol Gelling 
 
Term      Coef   SE Coef    T      P 
Constant  6.787   7.5083  0.904  0.384 
HPMC      1.343   0.4854  2.766  0.017 
 
 
S = 6.86435    PRESS = 797.327 
R-Sq = 38.94%  R-Sq(pred) = 13.90%  R-Sq(adj) = 33.85% 
 
 
Analysis of Variance for Alcohol Gelling 
 
Source          DF  Seq SS  Adj SS  Adj MS     F      P 
Regression       1  360.60  360.60  360.60  7.65  0.017 
  Linear         1  360.60  360.60  360.60  7.65  0.017 
    HPMC         1  360.60  360.60  360.60  7.65  0.017 
Residual Error  12  565.43  565.43   47.12 
  Lack-of-Fit    1   40.52   40.52   40.52  0.85  0.377 
  Pure Error    11  524.91  524.91   47.72 
Total           13  926.03 
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API in water (9.8%) and alcohol (20.2%) could be achieved by using HPMC even at lower 
concentrations (10% w/w level), when other factors are utilized at appropriate concentrations in 
the formulation.  
In order to validate the developed model, a confirmation batch utilizing PEO-301, HPMC 
K15M, and CBP at 20%, 10% and 6% w/w, respectively, was produced and analyzed. The 
predicted values obtained from the response optimizer were found to be similar to the observed 
values of 9.4% and 19.5% respectively, for percentage API extracted in water, and percentage 
API extracted in alcohol demonstrating the validity of the developed model. This final 
formulation was studied for drug release along with other TR properties and found that almost 
60-70% of the drug was released in 2-3hrs (data not presented). Although extended release 
polymers such as PEO-301 and HPMC K15M were used as carrier matrices in the present study, 
the observed faster dissolution rate in the initial hours could be attributed to the high water 
solubility of the LID, as well as utilization of lower molecular weight PEO (PEO-N80) as a filler 
in the formulation, which does not swell to a great extent and compromises the integrity of the 
gel network relatively quickly as opposed to high molecular weight grade PEO polymers.  
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Figure 1-7: Standardized Residual Plots on the Final Reduced Models for the Responses: 
(A) Percent API Extracted in Water; (B) Percent API Extracted in Alcohol 
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Figure 1-8: Response Optimization Plot for the HPMC (the only Significant Factor) on the 
Responses: (A) Percent API Extracted in Water; (B) Percent API Extracted in Alcohol 
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1.5. Conclusion 
HME was demonstrated as a viable technique for the development of much needed 
abuse-deterrent formulations. Moreover, high molecular weight grade polyethylene oxide was 
shown to be utilized as a TR matrix, while HPMC K15M in combination with CBP significantly 
improved the gelling characteristics in water and alcohol to prevent API extraction. The 
optimized response models created for ‘percentage API extracted in water’ and ‘percentage API 
extracted in alcohol’ also correlate well with the data generated, confirming its validity. Our 
future studies will be focused to work with controlled substances as model drugs, and evaluate 
newer excipients in conjunction with appropriate processing conditions to further improve the so 
far developed formulation and fully characterize its dissolution and stability characteristics. 
Although these formulations are termed as AD/TR dosage forms, these can never be completely 
abuse-free as none can stop a determined person from abusing the drugs. Still, these developed 
formulations would most likely serve the purpose as the abusers might definitely need to perform 
an enormous amount of work, or exhibit uncharacteristic patience, to use them in an unintended 
way. These formulations could also significantly reduce the deaths due to overdose, as well as 
decrease the percentage of young children and patients with acute or chronic pain who might 
convert into potential abusers.  
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CHAPTER - 2 
Characterization of Kollidon
®
 VA 64 Hot Melt Extrudates: Influence of Formulation and 
Process Parameters on Dissolution and Stability Characteristics 
 
2.1.Introduction 
In the recent years, several therapeutic compounds of complex nature were produced as a 
result of high throughput screening and combinatorial chemistry. It has been estimated that more 
than 40% of all of these produced new molecular entities suffer from solubility-limited 
bioavailability. Oral delivery of such compounds presents one of the most frequent and 
formidable challenges to formulation scientists. Myriad techniques such as spray drying (23), 
solvent-evaporation (24), nanocrystal formation (25), complexation (26), and micronization of 
API (27) etc., have been widely utilized in the industry to demonstrate the improved solubility 
and/or dissolution rate of such BCS Class II drugs, thereby enhancing their bioavailability. In 
addition, over the past couple of decades, HME technique has gained enormous interest amongst 
researchers in improving the bioavailability of drug substances, especially those having low 
water solubility, by formation of molecular dispersions (13, 14, 16, 17). Compared to other 
techniques HME offers several advantages such as being solvent free and involving fewer 
processing steps.  
 HME is the process of pumping raw materials with a rotating screw under elevated 
temperature through a die into a product of uniform shape. These final extrudates obtained 
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utilizing thermal energy may be in the form of films or rods that can be cut as tablets or pellets. 
To date, several research papers have been published by scientists that focused on the  
preparation of solid dispersions/solutions of numerous model drugs with low solubility such as 
Clotrimazole (CTZ), Indomethacin and Nifedipine (NIF) etc. utilizing HME technique. Shibata 
et al. produced solid solution of Indomethacin and crospovidone using twin-screw extruder, and 
demonstrated that the parameters such as residence time, screw speed and heating temperature 
play a significant role in the extrusion process (28). On the contrary, in a study by Verhoeven et 
al., the effect of process parameters (screw design, feed rate and screw speed) on Metoprolol 
tartarate and ethyl cellulose mini matrices were studied, and revealed that the process parameters 
had no significant influence on drug quality as well as drug release, indicating robustness of 
HME technique (29). In addition, the role of kneading paddle elements and operating conditions 
of twin screw extruder on NIF and HPMCP extrudates
 
were studied by Nakamichi et al. (30), 
and concluded that all of these factors played an important role in obtaining ideal solid 
dispersions. Most of these previous studies reveal that the influence of process parameters 
primarily depends on multiple factors such as the API involved, the carrier matrix utilized, and 
the processing conditions employed during the HME process.  
In the current study, NIF (a dihydro pyridine calcium channel antagonist) was employed 
as a model drug and Kollidon
®
 VA 64 as the polymeric matrix. NIF is a light sensitive yellow 
powder, practically insoluble in water, with a melting point of 172-174°C. It is a calcium channel 
blocker used in the treatment of hypertension and angina. NIF is currently available as both 
immediate and extended release tablet dosage forms given at a dose of 10-30 mg t.i.d. and 30-60 
mg once daily, respectively, depending on the patient’s condition. The utilized polymer matrix, 
 31 
Kollidon
®
 VA 64, is a vinyl pyrrolidone/vinyl acetate copolymer in 6:4 ratios. It is a hygroscopic 
white powder, soluble both in water and alcohols and has a glass transition temperature around ~ 
106°C. It has several pharmaceutical applications such as a binder in tablets, a granulating agent 
and a film former. The properties such as poor API oral-bioavailability of 45-56% due to 
solubility limitations, and the soluble nature of the polymer, including its lower glass transition 
temperature make them an appropriate choice as the drug and the carrier for HME processing at 
relatively lower temperatures. 
The nature of Kollidon
®
 VA 64 as a matrix polymer in HME has been previously studied 
by the researchers to some extent. Rapidly disintegrating tablets containing Indomethacin and 
Kollidon
®
 VA 64 extrudates were prepared by Dinunzio et al., and the authors studied the use of 
Ceolus(™) microcrystalline cellulose in producing these tablets (31). In addition, Jijun et al. has 
prepared the solid dispersion tablets of Nimodipine with a mixture of Eudragit
®
 EPO and 
Kollidon
®
 VA 64 by combining HME with direct compression, to improve its dissolution 
behavior in different media (32). However, a further in-depth characterization of the Kollidon
®
 
VA 64 hot melt extrudates involving the processing and formulation parameters is warranted for 
a thorough understanding of the formed dispersion systems utilizing this polymer. Therefore, in 
the current study, we have extensively studied the influence of various process parameters such 
as screw speed and extrusion temperature, and formulation factors such as drug load, plasticizer 
type and concentration on extrudability, drug release, and stability. In addition, the effect of 
moisture on content uniformity and dissolution, and effect of extrusion on powder flow 
characteristics have also been studied.  
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2.2.Materials and Methods 
2.2.1. Materials 
Nifedipine USP was purchased from LETCO Medical (Decatur, AL, USA); polyethylene 
glycol 3350, triethyl citrate, stearic acid, vitamin E succinate, propyl paraben, sodium lauryl 
sulfate (SLS), potassium phosphate monobasic, and sodium hydroxide were obtained from 
Fisher Scientific (Fair Lawn, NJ, USA). Kollidon
®
 VA 64 was kindly gifted by BASF 
Corporation. High performance liquid chromatography (HPLC) grade water was freshly 
prepared in the laboratory by Nanopure systems (Barnstead, Dubuque, IA, USA). All solvents 
utilized in the study were of analytical grade and obtained from Fisher Scientific (Fair Lawn, NJ, 
USA). 
2.2.2. Analytical Method 
In-house reverse phase high performance liquid chromatography (HPLC) based 
analytical method was developed for determination/quantification of NIF, and validated 
according to ICH and FDA guidelines for chromatographic method. An HPLC equipped with 
UV detector, Waters Symmetry shield 5μ C18 column (250×4.6 mm), and an isocratic mode of 
elution with mobile phase containing acetonitrile and water (55:45) at a flow rate of 1.0 mL/min 
were employed to quantify the drug at a wavelength (λmax) of 235 nm. The acquired data was 
processed using Empower 2 build 2154 software (Waters Inc., Mount Holly, NJ, USA). 
2.2.3. Solubility Parameter Calculations 
Hansen solubility parameters were obtained from the literature, and for materials not 
referenced in the literature were calculated based on their molecular structure and melting point 
using Molecular Modeling Pro, v6.2.8 (ChemSW, Fairfield, CA). 
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2.2.4. Thermal Gravimetric Analysis (TGA) 
The thermal stability of the NIF, Kollidon
®
 VA 64, their physical mixture and the melt 
extruded samples was determined as a function of weight loss. The analysis was performed on 
the samples (4-5 mg approximately) using a Perkin-Elmer Pyris 1 thermo-gravimetric analyzer 
(Norwalk, CT) operated a ramp rate of 20°C/min from a temperature of 50°C to 250°C. The % 
weight loss for all of the samples tested was recorded using the Pyris 1 TGA software. All of the 
TGA runs were performed in an open pan with purge and protective nitrogen gas flow at 40 
mL/min. 
2.2.5. Differential Scanning Calorimetry (DSC) Analysis 
DSC was used to characterize the miscibility of NIF in a polymeric carrier, Kollidon
®
 
VA 64, utilizing a Perkin-Elmer Diamond DSC instrument (Shelton, CT). A 2-3 mg sample of 
the pure drug and the polymer, and their physical mixtures with varying drug concentrations (5, 
10, 20, 40, 60, and 80%) were weighed, sealed in aluminum crimped pans (Kit 0219-0062, 
Perkin-Elmer Instruments, Shelton, CT), and heated from 40 to 245°C at a ramp rate of 
20°C/min under nitrogen purge at a flow rate of 20 mL/min. The hot melt extrudates were 
prepared by varying the drug concentrations as mentioned above, and subjected to an initial heat-
cool cycle (by heating to 140°C at the rate of 20°C/min and held for 5 min followed by cooling) 
to remove the thermal history of the samples. A second heat cycle was initiated wherein the 
samples were heated from 40 to 230°C at a ramp rate of 20°C/min under nitrogen purge at a flow 
rate of 20 mL/min. 
2.2.6. Hot Melt Extrusion (HME) 
NIF and Kollidon
® 
VA 64 were used as a model drug and carrier matrix, respectively. 
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Prior to processing, required materials previously sieved through mesh # 40 were accurately 
weighed, premixed in a mortar and pestle to get a homogeneous mixture. The resultant blend was 
further mixed in a twin-shell dry V-blender (The Patterson-Kelly co., Inc. East Stroudsburg, PA) 
at a speed of 25rpm for 10 minutes. Each of these resultant drug-polymer binary mixtures 
containing 25% of the drug were extruded at three different temperature profiles (115, 135, and 
155°C) utilizing a bench top co-rotating twin-screw hot melt extruder (Prism 16mm EuroLab, 
Thermo Electron Corporation, Newington, NH) using 8 mm round opening die. Also, at each of 
the temperature profiles three different screw speeds of 25, 50, and 100 rpm were employed and 
a total of nine hot melt extrudates of the same formulation were obtained to study the effect of 
process parameters. In addition, effect of processing aids and extrudates containing 10%/90% 
w/w and 40%/60% w/w drug/polymer mixtures were produced utilizing HME to study the effect 
of drug load. All of these final extrudates obtained were stored in foil-lined polyethylene bags 
and stored in a refrigerator until further analysis.  
2.2.6.1.Post-Processing Drug Content 
A portion of all of these extruded formulations were crushed into fine powder using 
mortar and pestle and stored in amber colored glass bottles. These processed and powdered 
extrudates were analyzed for the drug content immediately after extrusion through the hot melt 
extruder. A known amount of the extrudates and physical mixture were dissolved in 3:2 
methanol: water, diluted and filtered using 0.2 µm, 13 mm PTFE membrane filters (Whatman, 
Piscataway, NJ) and analyzed utilizing a HPLC at a wavelength of 235 nm. 
2.2.7. X-Ray Diffraction (XRD) Testing 
XRD testing was conducted using a Philips Model 1710 X-ray diffractometer (Philips 
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Electronic Instruments Inc., Mahwah, NJ) to assess crystallinity in conjunction with thermal 
techniques. Powders of the pure drug sample (NIF), the polymer (Kollidon
®
 VA 64), physical 
mixture, and the hot melt extrudates were passed through a # 40 mesh screen prior to the testing. 
Physical mixtures were prepared by pre-mixing NIF and Kollidon
®
 VA 64 in the appropriate 
ratio (25% drug/75% polymer). Instrument was operated at an accelerating voltage of 40 kV and 
30 mA. Samples of powder were placed into channeled stages and the diffraction profile was 
measured from 3.0
o
 to 50.0
o
 using a 2θ step size of 0.02o and dwell time of 3s.  
2.2.8. Moisture Absorption Study 
In order to investigate the extent of moisture absorption by the drug, polymer, (1:3; drug: 
polymer) physical mixture, and the hot melt extruded binary samples in the ratios of 1:9, 1:3, and 
2:3 of drug: polymer produced by the previously described methods, each of the samples was 
placed in a 40°C/75%RH environment, in opened amber colored borosilicate glass bottles for 7 
days. In addition, the HME samples were also compared before and after moisture absorption for 
content uniformity. 
The moisture absorbed by the samples is reported in terms of their % weight gain and 
was calculated by the following procedure. A sample of approximately 200 mg was weighed and 
placed in opened amber glass bottles which were equilibrated at 40°C/75%RH. The % weight 
gain (G) of samples was calculated using equation 3 provided below: 
 ---------- Equation 3 
Where  is the weight of the sample before moisture absorption,  is the initial weight of a 
glass bottle with sample (before moisture absorption) and  is the final weight of a glass bottle 
with sample (after moisture absorption). All measurements were performed in triplicate and were 
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compared with the initial data.  
2.2.9. Flow Properties 
The pure polymer, drug-polymer physical mixtures with varying drug loads (10, 25 & 40% 
w/w), and their corresponding extrudates have been assessed for their flow characteristics using 
traditional “angle of repose” measurement. In this experiment, a funnel was set to a fixed height 
using a clamp such that the distance between the lower tip of the funnel and the surface of a 
graph paper placed below is constant. The powder was slowly poured through the funnel on to 
the paper until the bulk material forms a conical pile, with its tip touching the base of the funnel. 
The angle of repose for each of these powders was then measured by the equation 4 provided 
below:  
 --------- Equation 4 
In the above equation, ‘h’ is the height of the pile of powder, and‘d’ is the diameter of the 
surface covered by the powder. 
2.2.10. In vitro Dissolution Testing 
Dissolution testing (USP XXXI, Apparatus I) was performed utilizing a Hanson SR8-
plus™ dissolution test station (Hanson Research Corporation, Chatsworth, CA) operated at 50 
rpm paddle speed. Drug release from the formulations extruded by varying the process 
parameters were evaluated for their release. Moreover, the effect of drug loaded samples (10%, 
25%, and 40% w/w) were compared before and after moisture absorption for drug dissolution. 
An amount equivalent to 25.0 mg NIF (theoretical drug loading) from the physical mixture and 
the hot melt extrudates previously ground in mortar and pestle was accurately weighed and filled 
in gelatin capsule # 3. These capsules were added to the dissolution vessel containing 900mL of 
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pH 6.8 phosphate buffer with 1% w/v sodium lauryl sulfate (SLS) preheated to 37°C. During 
testing 1.5mL samples were removed from the dissolution vessels at pre-determined time 
intervals and replaced with an equal volume of fresh dissolution medium. Samples were 
immediately filtered using 13 mm PTFE membrane filters (Whatman, Piscataway, NJ) with a 
pore size of 0.2 µm and analyzed using HPLC at a λmax of 235nm. Drug concentration was 
calculated from a standard calibration plot and expressed as cumulative % drug dissolved. The 
release studies were also performed in triplicate and the mean values were compared.  
2.2.11. Stability Studies 
A portion of NIF-Kollidon
®
 VA 64 extrudates produced were stored in amber colored 
borosilicate glass bottles at 3 different temperatures of 4, 25 and 40°C and analyzed at pre-
determined time intervals for the amount of NIF present using HPLC. The stability of these 
extrudates was then compared to the physical mixture. The results of the stability studies are 
expressed as a percentage of NIF degraded at various time intervals. 
2.2.12. Statistical analysis 
 To compare between different formulations, statistical analysis was performed utilizing 
one way analysis of variance (ANOVA). A statistically significant difference was considered 
when P<0.05.  
2.3.Results and Discussion 
2.3.1. Analytical Method 
Validation was carried out as per the ICH and FDA guidelines for the chromatographic 
method development. The linear calibration range for the detection of NIF was found to be 5-200 
μg/mL, with the co-efficient of determination (R2) of 0.999. The limit of detection and 
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quantitation for the drug were 0.2 and 1.0 µg/mL, and the retention time for the NIF was ~7.8 
minutes. The % relative standard deviation (RSD) within replicates (n=3) was less than 2%, 
demonstrating reproducibility of the method. Precision was tested by injecting a single drug 
concentration of 20μg/mL, and the peak area (n=10) was recorded. A superior precision was 
observed with less than 0.5% of RSD.  
2.3.2. Solubility Parameter Calculations 
A three dimensional Hansen solubility parameter obtained from either literature or 
Molecular Modeling Pro
TM
 software represents dispersive, polar and hydrogen bonding 
interactions of a molecule, and it could be used to estimate the interactions amongst the 
components in a formulation (33). From a pharmaceutical applications standpoint, this parameter 
is a very useful tool in predicting the API morphology and drug-polymer miscibility in the solid 
dispersions and the drug-excipient interactions in the development of solid oral dosage forms. 
The effective solubility parameter obtained from Hansen method for NIF and Kollidon
®
 VA 64 
were 17.9 MPa
1/2 
and 21.1 MPa
1/2
, respectively. Theoretically, in order to observe at least partial 
miscibility between the drug and the polymer, the solubility parameter difference (Δδ) between 
them is required to be at least less than 7.0 MPa
1/2 
(34, 35). In the present scenario, Δδ is 3.2, 
which is significantly less than 7.0 MPa
1/2
, indicating the NIF miscibility in the utilized carrier 
matrix to form a solid dispersion. 
2.3.3. Thermal Gravimetric Analysis  
It is very crucial to study the thermal profiles of the active and the individual excipients 
present in a formulation, prior to melt extrusion. In order to evaluate the active and excipients 
processability and stability during extrusion, the materials were subjected to heat ramp and 
identified that both, pure components and their physical mixture, exhibited less than 2% weight 
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loss throughout the temperature range studied (Figure 2-1). Therefore, it has been concluded that 
the processing temperatures under study are suitable to evaluate; however, it should be noted that 
heat ramp was very quick in case of TGA study and the outcome of prolonged exposure of the 
components to such high temperatures is not yet clear and requires further investigation. 
 
Figure 2-1: An Overlay of Thermogravimetric Analysis Profiles of Nifedipine, Kollidon
®
 
VA 64, 25% Nifedipine – 75% Kollidon® VA 64 Physical Mixture, and their Corresponding 
Hot Melt Extrudates 
 
2.3.4. Differential Scanning Calorimetry Analysis 
Solid dispersion has been one of the promising approaches utilized to enhance the 
dissolution rate of the poor-soluble actives. An important prerequisite to attain the solid 
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dispersion formation is miscibility or interaction between the API and polymeric components in 
a formulation. In the present study, the miscibility of NIF at various concentrations in Kollidon
®
 
VA 64 carrier matrix was investigated using Perkin-Elmer diamond DSC. In the thermograms 
shown in Figures 2-2A and 2-2B, temperature is plotted on the X-axis and heat flow (Endotherm 
up) on the Y-axis. The DSC thermogram of the pure drug revealed a characteristic melting 
endotherm of NIF at 172-174°C (36), while the physical mixtures exhibited a slight melting 
point depression of the drug in presence of the polymer, indicating its miscibility in the carrier 
matrix. NIF was completely miscible only at a concentration of 5% w/w in the physical mixtures, 
whereas the hot melt extrudates demonstrated good miscibility of the drug (up to 40% w/w) in 
the polymeric matrix. The peak corresponding to the melting of NIF was clearly evident in the 
DSC thermogram of the physical mixtures at 40% w/w of the active, whereas it disappeared in 
the melt extrudates (loss of crystallinity) at same drug load. This could be attributed to the 
formation of an amorphous solid dispersion of NIF in the Kollidon
®
 VA 64 matrix. However, 
NIF at a concentration of 60% and 80% w/w in the melt extrudates does not seem to be 
completely miscible. 
 41 
 
 
Figure 2-2: DSC Thermograms of (A) Pure Nifedipine, Kollidon
®
 VA 64 and the 
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Nifedipine/Kollidon
®
 VA 64 Physical Mixtures with Varying Drug Loads, and (B) Pure 
Nifedipine, Kollidon
®
 VA 64 and the Nifedipine/Kollidon
®
 VA 64 Hot Melt Extrudates with 
Varying Drug Loads 
2.3.5. Hot Melt Extrusion (HME) 
2.3.5.1.Effect of processing parameters (Temperature and Screw speed) 
The process parameters employed in the study are provided in Table 2-1. All of the 
formulations exhibited a maximum die pressure of 6-7 bars, and the material feed rate was 
consistent in each case. The extrudates processed at lower barrel temperatures (115 and 135°C), 
irrespective of screw speeds, exhibited higher post-processing drug content (97-100%). 
Table 2-1: Various Processing Parameters Employed, and Responses Observed During 
HME 
Extrusion Temperatures (deg C) 115 135 155 
Extrusion Speeds (rpm) 25 50 100 
Residence Time (min) 6 to 7 3 to 4 1 to 2 
Observed Max Die Pressure 6 to7 bars 
Torque Maintained 50%-60% - (12 - 15 Nm) 
 
 
However, those processed at a higher extrusion temperature of 155°C, the post-
processing drug content decreased with decrease in screw speed from 100 to 25rpm (Figure 2-3). 
In particular, the formulation produced at a higher temperature (155°C) and lower screw speed 
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(25rpm) exhibited only 45% drug remaining, post-process. The lower screw speed of 25rpm 
displayed relatively longer material residence time in the extruder barrel (approximately 6-7 
minutes) in comparison to the higher screw speeds, and the exposure of the active at 155°C for 
such a long period might have caused drug degradation. The results were in accordance with the 
findings of Caira et al., where the authors identified an existence of a solvated crystal form of 
NIF using single-crystal X-ray technique, which undergoes de-solvation leading to a complete 
disruption of crystal structure and conversion into a thermo-sensitive monoclinic polymorph at 
relatively high temperatures of 150-153°C (36). Both of the processing parameters, temperature 
and screw speed, were found to have a significant impact on the post-processing drug content of 
the final extrudates. 
 
Figure 2-3: Effect of Processing Parameters on Post-Processing Drug Content in 
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Nifedipine/Kollidon
®
 VA 64 Hot Melt Extrudates. Data Represent Mean ± S.D (n=6) 
2.3.5.2.Effect of formulation factors: Drug load and Process aids 
It was identified from the process evaluation that use of lower temperatures was suitable 
to produce reasonable extrudates with minimal drug degradation. Consequently, 10%, 25%, and 
40% w/w NIF formulations were extruded at 135°C and 50rpm screw speed, which resulted in 
formulations with excellent post-processing drug content (99-100%) in the formulations, with no 
sign of drug degradation. The drug concentrations in the formulations were chosen based on the 
results obtained from preliminary DSC studies that supported formation of solid dispersions in 
mixtures comprising up to 40% w/w drug.  
Furthermore, to produce a flexible formulation with greater ease and at lower 
temperatures, processing aids are very essential. Kollidon
®
 VA 64, as mentioned earlier, softens 
above 100°C and may necessitate the use of a processing aid in order to produce a uniform melt 
at relatively low process temperatures. For this purpose, several hydrophilic and hydrophobic 
additives such as polyethylene glycol 3350, triethyl citrate, stearic acid, vitamin E succinate, and 
propyl paraben, each at two different concentrations (2.5% and 5% w/w), were investigated as 
process aids to evaluate their miscibility in drug-loaded Kollidon
®
 VA 64 blend. Each of these 
physical mixtures, in the preliminary set of experiments, containing 25% w/w drug, 70-72.5% 
w/w of the polymer, and the processing aids was prepared into polymeric patches via casting 
method on a heated brass plate at 130°C using a punch and 8 mm round die, and their properties 
were observed visually for flexibility and texture. None of the chemical processing aids utilized 
in the formulation exhibited flexibility in the melt casted films of the polymeric carrier. 
Moreover, they produced either glassy or sticky products at the concentrations employed. 
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Nevertheless, Kollidon
®
 VA 64 was extrudable at 90% w/w, with only a model drug in the 
formulation. 
2.3.6. X-Ray Diffraction (XRD) Testing 
DSC studies indicated the drug-polymer miscibility in the hot melt extruded formulations 
(data not shown), which has been further confirmed by the XRD analysis. The diffraction pattern 
of pure NIF exhibited sharp and highly intense peaks at 2θ degrees of 8.0, 11.9, 19.5, and 24.0, 
indicating crystalline nature of the drug (37). However, the physical mixtures containing drug 
and polymer at 1:3 ratios, when subjected to X-ray diffraction, exhibited relatively less intense 
and more diffused peaks, but the 2θ angles of the peaks remained unaffected (Figure 2-4). These 
changes in peak intensity could be attributed to the dilution of the active in the Kollidon
®
 VA 64 
matrix, and the unchanged 2θ angles of the peaks indicate existence of original crystalline form 
of the drug in the physical mixture. On the contrary, XRD pattern of melt extruded formulations 
produced using different process parameters did not demonstrate any sign of crystallinity or 
characteristic peaks at specific 2θ angles, indicating formation of an amorphous solid dispersion 
in those formulations. This data further strengthens the DSC results discussed earlier, where the 
active was completely miscible in the melt extrudates up to 40%w/w with no sign of 
characteristic melting endotherm of NIF. 
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Figure 2-4: X-ray Diffraction Patterns of Nifedipine, Kollidon
®
 VA 64, Drug/Polymer 
Physical Mixture (1:3), and their Corresponding Melt Extruded Sample Produced at 135°C 
and 50 rpm Screw Speed 
2.3.7. Moisture Absorption Study 
It was hypothesized that variability in the intimacy of mixing in different powder samples 
would be explained by investigating the extent of moisture absorption, which is directly 
proportional to the amount of hygroscopic surface area of the material being tested (38). Thus 
extent of moisture absorption could be an indicative of the intimate mixing of powders, and high 
moisture content in the powder mixtures could lead to inconsistency in the drug content and drug 
dissolution. In the present study, the extent of moisture absorption is estimated by percentage 
weight gained by the powder mixtures, when subjected to high relative humidity conditions. 
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Although mixtures were exposed to high humidity conditions for 7 days, all of the samples under 
test reached equilibrium within 24 hours. The hot melt extrudates (at 25% w/w drug loading) 
exhibited 15-20% decrease in weight gain compared to their corresponding physical mixture, and 
about 30% decrease in weight gain in comparison to the pure polymer, when subjected to the 
same conditions. Amongst the hot melt extrudates, the formulations produced utilizing different 
process temperatures and screw speeds did not demonstrate any significant difference in % 
moisture absorbed (data not presented), indicated by unchanged percentage weight gain of the 
mixtures. However, the weight gain in the milled extrudates decreased from 20% to 45% as the 
drug concentration increased from 10% to 40% w/w, in comparison to the pure polymer (Figure 
2-5). This decrease in the % weight gain or reduced moisture uptake could be attributed to the 
presence of low concentrations of hygroscopic polymer in the formulations with higher drug 
load.  
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Figure 2-5: Moisture Absorption Study of Nifedipine, Kollidon
®
 VA 64, Drug/Polymer 
Physical Mixture (1:3), and the Milled Extrudate Samples Produced at Varying Drug 
Loads. Data Represent Mean ± S.D (n=3) 
Additionally, content uniformity of NIF in the milled hot melt extrudates containing 10%, 
25% and 40% w/w drug loads, prior to and after exposure to high humidity conditions for a 
period of 7 days was evaluated. From the data presented in Figure 2-6, it is obvious that the 
milled extrudate samples did not show any great change in the drug content uniformity before 
and after being exposed to high moisture environment, irrespective of their drug concentrations. 
Although the % weight gain varied amongst milled extrudates with different drug loading, the 
drug distribution within the polymeric mixtures was not affected by the presence of moisture. 
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This could be due to the drug being uniformly distributed at a molecular level in the polymeric 
matrix, during HME process, which provides intimate contact of both the components in a 
formulation.  
  
Figure 2-6: Content Uniformity of Nifedipine in the Milled Hot Melt Extrudates 
Containing 10%, 25% and 40% W/W Drug Loads and in 25% Drug-75% Polymer 
Physical Mixture Prior to, and After Exposure to High Humidity Conditions. Data 
Represent Mean ± S.D (n=3) 
2.3.8. Flow Properties 
Manufacturing dosage forms such as tablets and capsules is very simple and cost-
effective approach that has been in practice over many decades. In order to produce such 
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formulation with good content uniformity, it is essential to consider the powder characteristics 
such as particle shape, density, coefficient of friction of the material etc. Angle of repose, 
utilized to measure the flow properties, is also related to these attributes mentioned above. 
Smaller angles correspond to wide spread of the bulk material, indicating better flow. From the 
study results presented in Table 2-2, Kollidon
®
 VA 64 demonstrated superior flow by itself. 
However, an increase in the drug load from 10% w/w to 40% w/w in the physical mixtures 
resulted in larger angles that indicate poor flow characteristics. This behavior could be attributed 
to the difference in particle sizes between the API and the polymer, and to the cohesive nature of 
API diluting the free flowing polymer. 
Table 2-2: Flow Properties of the Drug-Polymer Mixtures before and after HME 
Samples 
Angle of Repose (θ) 
Prior to Extrusion Post Extrusion 
PVPVA 64 21.95 -- 
10% Drug Load 30.66 23.85 
25% Drug Load 37.88 24.32 
40% Drug Load 39.21 23.50 
 
On the contrary, similar binary physical mixtures when processed utilizing hot melt 
extruder followed by milling into fine powder, demonstrated superior powder flow 
characteristics independent of drug loading. A possible explanation for this observation could be 
formation of a solid dispersion post-extrusion, as previously confirmed by DSC and XRD 
studies, where drug dissolves at a molecular level in the hydrophilic polymer matrix resulting in 
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changing the API physical properties. Based on the results, it is obvious that HME technique 
could be utilized to enhance the flow characteristics of the bulk material that could potentially 
minimize the content uniformity issues in conventional dosage forms. Furthermore, morphology 
and physical properties of the active and other excipients chosen in a formulation would be 
important in governing the flow characteristics.  
2.3.9. In vitro Dissolution Testing 
Dissolution testing of the melt extrudates in vitro is another important aspect that gives an 
idea of how a formulation behaves in vivo in terms of drug release. All of the extruded 
formulations produced at different screw speeds and temperatures had shown similar release 
profiles; in addition, more than 90% of the drug was released within 1 hour from all of the 
formulations tested (Figure 2-7A & 2-7B). Similarity factor ‘f2’ was utilized to compare the 
dissolution profiles amongst different formulations (39), and was calculated using equation 5, 
where ‘n’ is the total number of sampling intervals and ‘Rt’ and ‘Tt’ are cumulative % drug 
released from reference and test formulations at any time interval ‘t.’ 
n
t
tt TR
n
f
1
5.02
2 }100])(
1
1log{[50 ---------- Equation 5 
 52 
 
 
Figure 2-7: Dissolution Profiles of Nifedipine/Kollidon
®
 VA 64 HME (A) Processed at 
135°C- Effect of Processing Speeds; and (B) Processed at 100rpm Screw Speed- Effect of 
Processing Temperatures. Data Represent Mean ± S.D (n=3) 
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All of the obtained f2 values, when compared amongst the dissolution profiles, were 
between 50 and 100 indicating that the drug release was similar for all of the formulations under 
investigation. Similarly, extrudates with varying drug loads of 10, 25 and 40% w/w were 
analyzed for the drug release, and their release patterns were presented in Figure 2-8.  
 
Figure 2-8: Drug Release from Nifedipine/Kollidon
®
 VA 64 Hot Melt Extrudates 
Containing Varying Drug Loads Produced at 135°C and 50rpm Screw Speed. Data 
Represent Mean ± S.D (n=3) 
The formulation containing 10% drug loading demonstrated a higher release rate 
compared to 25%, followed by 40% w/w drug load. The extrudates with lower drug 
concentration (10% w/w) behaved as an immediate release dosage form with more than 90% of 
the drug being released within 20 minutes, while those containing 25% w/w NIF loading 
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released the same within 60 minutes. Hence, it was obvious that the drug load has a greater 
impact on the release of the drug, and could be especially attributed to the presence of more 
amount of hydrophilic matrix, Kollidon
®
 VA 64, in the solid dispersion formulations containing 
10% w/w NIF. On the contrary, the hot melt extrudates containing 40% w/w NIF demonstrated 
slower drug dissolution in comparison to the extrudates with lower drug loading, which could be 
ascribed to the poor solubility and wettability of the active.  
In addition, drug release from the extrudates with varying drug concentrations was 
studied before and after subjecting to the moisture absorption study. There was no significant 
difference observed in the release profiles (data not shown) before and after the moisture 
absorption, at each of the drug loads tested. Moreover, release of NIF from the 25% w/w 
extrudates was found to be different, and significantly superior (Figure 2-8) compared to its 
corresponding 25% w/w physical mixture (f2=36.70). This is indicative of an improved drug 
dissolution rate from the extrudates in comparison to their corresponding physical mixtures, due 
to the formation of solid dispersion (previously evidenced by the DSC and XRD data) utilizing 
HME technique.  
2.3.10. Stability Studies 
Achieving a stable formulation with minimal or no API degradation throughout the 
product’s shelf-life is of paramount importance for any given dosage form. The conventional 
dosage forms have several excipients incorporated in their formulations that lead to an increased 
possibility of drug-excipient incompatibilities, resulting in drug degradation. On the contrary, hot 
melt extrudates in the present study have only drug-polymer binary mixture, which minimizes 
the risk of drug instability in the formulation. Additionally, it is also well known that temperature 
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is a key factor that influences the reaction rates, and plays an important role in chemical 
degradation (40). As per Arrhenius equation a pharmaceutical system under investigation, when 
subjected to excessive thermal exposure undergoes accelerated degradation. However, Arrhenius 
assumption may be often invalid because of the unexpected phase changes or adsorbed moisture. 
Hence, it is advisable to use the lowest temperatures for the study that produces measurable 
failure in allocated time. Considering the fact, the chemical stability of the extruded formulations 
was studied by storing the samples at three different temperatures (4, 25 and 40°C) and analyzing 
them for % active remaining in the extrudates, which represents the scale on Y-axis (Figure 2-9). 
The API degradation in all of the formulations under study was found to be less than 5% for up 
to 3 months (period of study). These results indicate that the produced extrudates were 
chemically stable, and the processing conditions did not significantly impact the stability of NIF 
present in the extrudates.  
This data was further corroborated with the physical stability results. As previously 
mentioned, elevated temperatures promote the reaction rate by lowering the activation energy. 
Typical elevated storage temperature under practice for accelerated degradation of a 
pharmaceutical system is 40°C. Therefore, the physical stability of the extrudates stored at this 
temperature for three months was assessed for change in the crystallinity or amorphous nature of 
the formed solid dispersions.  
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Figure 2-9: Chemical Stability of Nifedipine/Kollidon
®
 VA 64 Hot Melt Extrudates 
Produced Utilizing Varying Processing Conditions, Stored at Three Different 
Temperatures for a Specific Period of Time. Data Represent Mean ± S.D (n=3) 
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Figure 10: XRD Patterns Indicating Physical Stability of Nifedipine/Kollidon
®
 VA 64 Hot 
Melt Extrudates Produced Utilizing Varying Processing Conditions, Stored at 40°C for a 
Specific Period of Time 
XRD patterns (Figure 2-10) of the extrudates under investigation did not demonstrate any 
sign of crystallization after exposing to elevated temperature for such a long period, signifying 
their physical stability. In addition, all of the extruded formulations with 10%, 25% and 40% 
drug loading were also found to be physically and chemically stable up to 3 months (data not 
presented) under employed conditions. 
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2.4.Conclusions 
In this study, melt extrusion technique in combination with Kollidon
®
 VA 64 produced 
stable extrudates with higher drug loading and superior drug release. NIF was found to be 
miscible in Kollidon
®
 VA 64 up to 40% w/w drug load, without having need of any processing 
aid for extrusion. Kollidon
®
 VA 64, on the other hand, was extrudable at 90% w/w with only a 
model drug in the formulation. The processing parameters had a significant impact on the post-
processing drug content, and the influence of drug load on release from extrudates was 
remarkable. These results demonstrate the importance of selecting appropriate carrier matrix for 
HME process, and utilizing suitable formulation and process conditions based on 
physicochemical properties of the active and the polymeric carrier under study, which could 
greatly influence the final properties of the produced extrudates.  
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CHAPTER - 3 
Characterization of Soluplus
®
 Hot Melt Extrudates: Effect of Formulation and Process 
Parameters on Miscibility, Dissolution and Stability Characteristics 
 
3.1.Introduction 
Advent of high throughput screening and combinatorial chemistry is resulting in more 
complex API (active pharmaceutical ingredient) structures. It has been estimated that 40-50% of 
all new molecular entities suffer from poor bioavailability due to low aqueous solubility (16). 
Formulation of such compounds for oral delivery presents one of the most frequent and 
formidable challenges to formulation scientists. Numerous techniques such as spray drying, 
solvent-evaporation, nano-crystal formation, complexation, and micronization of API etc., have 
been widely utilized in the industry to demonstrate the improved solubility and/or dissolution 
rate of such drugs, thereby enhancing their bioavailability (23-27). In addition, over the past 
couple of decades, HME technique has gained enormous interest amongst researchers in 
improving the bioavailability of drug substances, especially those having low water solubility, by 
formation of molecular dispersions (13, 14, 16, 17). HME offers several advantages such as 
being solvent free and involving fewer processing steps in comparison to other techniques.  
As mentioned earlier, HME is the process of pumping raw materials with a rotating screw 
under elevated temperature through a die into a product of uniform shape. These final extrudates 
obtained utilizing thermal energy may be in the form of films or rods that can be cut as tablets or 
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pellets. To date, several research papers have been published by scientists that focused on the 
preparation of solid dispersions/solutions of numerous poorly aqueous soluble model drugs such 
as CTZ, indomethacin and NIF etc. utilizing HME technique. In addition, different grades of 
hydrophilic and hydrophobic polymers such as PolyOx™, Eudragit®, Kollidon®, Ethocel® were 
utilized to produce such dispersions, and were characterized in-depth using HME technique.  
Soluplus
®
, a recently introduced polymer, is mainly employed as the carrier matrix in the 
current study. Soluplus
®
 is a graft copolymer of PEG 6000/vinyl caprolactam/vinyl acetate 
copolymer in 13/57/30 ratios. It is white to yellowish free flowing granules with a glass 
transition temperature at ~70°C. The high flowability combined with its good extrudability 
characteristics demonstrate an excellent performance of the polymer in the formation of solid 
solutions, especially in HME processes. Due to the presence of PEG 6000, it is believed to have 
solubilization effect as well. Therefore, Soluplus
®
 combines the benefits of solid solutions and 
solubilization which thereby increases solubility of poorly soluble drugs and hence enhance 
bioavailability. The properties mentioned above makes Soluplus
®
 an attractive carrier matrix for 
HME processing, but to date, there is little research published on Soluplus
®
 and needs further 
evaluation. 
Lust et al. studied the formation of piroxicam solid dispersions using Soluplus
®
 as the 
carrier matrix. The authors concluded that Soluplus
®
 enhanced the dissolution as well as the oral 
bioavailability of piroxicam in rats (41). Solid dispersions of various drugs such as 
indomethacin, famotidine, camptothecin, and fenofibrate were also produced using this 
polymeric solubulizer, Soluplus
®
 (42-44). It is also been used in the preparation of bicalutamide 
nano-crystals which are produced by anti-solvent precipitation method (45). In addition, it is also 
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used as a carrier matrix in the preparation of carbamazepine-nicotinamide co-crystals (46). Apart 
from being used as a carrier matrix in HME, Soluplus
®
 has also been used in the electro-spinning 
and KinetiSol
®
 dispersing techniques as well (47, 48).  
In addition, many research scientists have also published the effect of process parameters 
during extrusion. Few examples are: Shibata et al. produced solid solution of Indomethacin and 
crospovidone using twin-screw extruder, and demonstrated that the parameters such as residence 
time, screw speed, and heating temperature play a significant role in the extrusion process (28). 
On the contrary, in a study by Verhoeven et al., the effect of process parameters (Screw design, 
feed rate and screw speed) on metoprolol tartarate and ethyl cellulose mini matrices were 
studied, and revealed that the process parameters had no significant influence on drug quality as 
well as drug release, indicating robustness of HME technique (29). In addition, the role of 
kneading paddle elements and operating conditions of twin screw extruder on NIF and HPMCP 
extrudates were studied by Nakamichi et al., and concluded that all of these factors played an 
important role in obtaining ideal solid dispersions (30). Most of these previous studies reveal that 
the influence of process parameters primarily depends on multiple factors such as the API 
involved, the carrier matrix utilized, and the processing conditions employed during the HME 
process.  
Therefore, in the current study, CTZ was utilized as a model drug, which is a practically 
water-insoluble antifungal agent with a melting point of 146-147°C, and Soluplus
®
 was used as a 
polymeric matrix to further investigate the feasibility of producing drug-loaded Soluplus
®
 
extrudates. Solid dispersions in the present study were produced using a MiniLab II HAAKE 
Rheomex CTW5 (conical twin-screw compounder) manufactured by ThermoFisher Scientific. In 
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early drug development stages, very less quantities of drug is available to conduct the feasibility 
studies. In such circumstances, this kind of equipment is well suited as the minimum quantity 
required for this extruder is only 5-10 gm. This manuscript illustrates the readers the effect of 
formulation and process parameters such as drug load and drug residence time on a much smaller 
scale, especially, when small amount of the drug is available. The influence of formulation and 
processing parameters such as drug-load and residence time, respectively, on the drug-polymer 
miscibility and drug release was also studied, including the physical and chemical stability of 
these extrudates.  
3.2.Materials and Methods 
3.2.1. Materials 
Clotrimazole USP was purchased from LETCO Medical (Decatur, AL, USA); 
Hydrochloric acid was obtained from Fisher Scientific (Fair Lawn, NJ, USA). Soluplus
®
 was 
kindly gifted by BASF Corporation. High performance liquid chromatography (HPLC) grade 
water was freshly prepared in the laboratory by Nanopure systems (Barnstead, Dubuque, IA, 
USA). All solvents utilized in the study were of analytical grade and obtained from Fisher 
Scientific (Fair Lawn, NJ, USA). 
3.2.2. HPLC Analysis 
In-house reverse phase high performance liquid chromatography (HPLC) based 
analytical method was developed for determination/quantification of CTZ. An HPLC equipped 
with UV detector, Novapak phenyl column (150×4.6 mm) with particle size of 3μ, and an 
isocratic mode of elution with mobile phase containing methanol and 25mM KH2PO4 buffer 
(80:20) at a flow rate of 1.0 mL/min were employed to quantify the drug at a wavelength (λmax) 
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of 215 nm. All injections were performed by an autosampler, and the injection volume was 
20µL. The acquired data was processed using Empower 2 build 2154 software (Waters Inc., 
Mount Holly, NJ, USA). 
3.2.3. Thermal Gravimetric Analysis (TGA) 
The thermal stability of the CTZ, soluplus
®
, and their physical mixture samples was 
determined as a function of weight loss. The analysis was performed on the samples (4-5 mg 
approximately) using a Perkin-Elmer Pyris 1 thermo-gravimetric analyzer (Norwalk, CT) 
operated at a ramp rate of 20°C/min from a temperature of 40°C to 250°C. The % weight loss for 
all of the samples tested was recorded using the Pyris 1 TGA software. All of the TGA runs were 
performed in an open pan with purge and protective nitrogen gas flow at 40 mL/min. 
3.2.4. Differential Scanning Calorimetry (DSC) Analysis 
DSC was used to characterize the miscibility of CTZ in a polymeric carrier, soluplus
®
, 
utilizing a Perkin-Elmer Diamond DSC instrument (Shelton, CT). A 2-3 mg sample of the drug, 
polymer, and physical mixtures with varying drug concentrations (10, 20, 30, 40, and 50%) were 
weighed, sealed in aluminum crimped pans (Kit 0219-0062, Perkin-Elmer Instruments, Shelton, 
CT), and heated from 30 to 210°C at a ramp rate of 20°C/min under nitrogen purge at a flow rate 
of 20 mL/min. The hot melt extruded samples were subjected to an initial heat-cool cycle (by 
heating up to 130°C at the rate of 20°C/min and held for 5 min followed by cooling) to remove 
the thermal history of the samples. A second heat cycle was initiated wherein the samples were 
heated from 40 to 210°C at a ramp rate of 20°C/min under nitrogen purge at a flow rate of 20 
mL/min. In addition, the extruded samples with 30% drug load were subjected to prolonged heat 
exposure (varying residence time of 1, 5, and 10 min) at a barrel temperature of 130°C, and their 
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thermal characteristics were also studied. 
3.2.5. Hot Melt Extrusion (HME) 
CTZ and soluplus
®
 were used as a model drug and carrier matrix, respectively. Prior to 
processing, required materials previously sieved through mesh # 40 were accurately weighed and 
were further blended in a twin-shell dry V-blender (The Patterson-Kelly co., Inc. East 
Stroudsburg, PA) at a speed of 25rpm for 10 minutes. The CTZ-Soluplus
®
 binary mixtures 
containing 10%, 20% and 30% of the drug load were extruded at 130°C and 70 rpm screw speed 
utilizing a conical twin screw compounder (MiniLab II HAAKE Rheomex CTW5, ThermoFisher 
Scientific). The torque (N-cm) and the pressure difference (ΔP) generated during the extrusion 
process were recorded. 
In addition, to assess the effect of processing time, each of the above produced 
formulations were exposed at 130°C for 1, 5 and 10 minutes. All of these final extrudates 
obtained at each of the mentioned conditions were stored in foil-lined polyethylene bags and 
stored in a refrigerator until further analysis.  
3.2.5.1.Post-processing Drug Content 
A portion of all of these extruded formulations were crushed into fine powder using 
mortar and pestle and stored in amber colored glass bottles. These processed and powdered 
extrudates were analyzed for the drug content immediately after extrusion through the hot melt 
extruder. A known amount of the extrudates and physical mixture were dissolved in 4:1 
methanol: water, diluted and filtered using 0.2 µm, 13 mm PTFE membrane filters (Whatman, 
Piscataway, NJ) and analyzed utilizing a HPLC at a wavelength of 215 nm. 
3.2.6. Fourier-transform infrared spectroscopy 
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FTIR spectra for the drug, polymer, and their extrudates produced with varying drug 
loads were obtained using a Perkin Elmer FTIR spectrometer (PerkinElmer Life and Analytical 
Sciences, Shelton, CT, USA). A spectrum was collected for each sample within the wave number 
region 4,000-400 cm
−1
. The spectra were analyzed for the absence or shift in the wave numbers 
of the characteristic peaks and reported.  
3.2.7. In vitro Dissolution Testing 
Dissolution testing (USP XXXI, Apparatus II) was performed utilizing a Hanson SR8-
plus™ dissolution test station (Hanson Research Corporation, Chatsworth, CA) operated at 50 
rpm paddle speed. Drug release from the formulations extruded at varying CTZ loads (10%, 
20%, and 30% w/w) were evaluated for their release. Moreover, the effect of residence time (1, 
5, and 10 minutes) on drug release from extrudates containing 30% CTZ was studied. A 60mg 
sample from each of the produced melt extruded formulations, previously ground in mortar and 
pestle, was accurately weighed and filled in gelatin capsule # 4. These capsules were added to 
the dissolution vessel containing 900mL of 0.1N hydrochloric acid (pH 1.2) preheated to 37°C. 
During testing 1.5mL samples were removed from the dissolution vessels at pre-determined time 
intervals and replaced with an equal volume of fresh dissolution medium. Samples were 
immediately filtered using 13 mm PTFE membrane filters (Whatman, Piscataway, NJ) with a 
pore size of 0.2 µm and analyzed using HPLC at a λmax of 215nm. Drug concentration was 
calculated from a standard calibration plot and expressed as cumulative % drug dissolved. The 
release studies were also performed in triplicate and the mean values were compared.  
3.2.8. Stability Studies 
A portion of CTZ-soluplus
®
 extrudates produced were stored in amber colored 
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borosilicate glass bottles at 3 different temperatures of 4, 25 and 40°C and analyzed at pre-
determined time intervals for the amount of CTZ present using HPLC. The chemical stability of 
these extrudates was then compared to the physical stability of the same assessed utilizing DSC 
after 3-month time point. The results of the chemical stability studies are expressed as a 
percentage of CTZ remaining at various conditions under investigation. 
3.2.9. Statistical analysis 
 To compare between different formulations, statistical analysis was performed utilizing 
one-way analysis of variance (ANOVA). A statistically significant difference was considered 
when P<0.05.  
3.3.Results and Discussion 
CTZ is an antifungal compound that acts primarily by altering the permeability of the cell 
wall and inhibiting the synthesis of ergosterol, which is required for the production of fungal cell 
membrane. This active has very poor aqueous solubility characteristics with erratic oral 
absorption, and therefore presents itself as a good candidate for HME processing to demonstrate 
an enhancement in its dissolution characteristics. Soluplus
®
, on the other hand, is a hydrophilic 
polymer that also exhibit solubilization capacity of poorly soluble drugs. 
As a part of pre-formulation studies, TGA was performed to demonstrate the heat 
stability and thermal processability of the drug and the polymer during melt extrusion process. 
The TGA studies revealed that Soluplus
®
 and CTZ were found to be stable under employed 
extrusion conditions with about 2% weight change being observed (Figure 3-1), when heated up 
to 250°C. An initial small decrease in the weights of the pure polymer and its corresponding 10% 
drug physical mixture at about 100°C could be due to the loss of water from the Soluplus
®
. 
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Figure 3-1: An Overlay of Thermogravimetric Analysis Profiles of Clotrimazole (CTZ), 
Soluplus
®
, and 10% CTZ – 90% Soluplus® Physical Mixture 
It was evident from the DSC studies of the physical mixtures that CTZ exhibited a 
melting endotherm at all of the studied concentrations, which indicates that the drug’s 
crystallinity is retained up on physical mixing with the polymer. However, a melting point 
depression of the drug was noticed in the presence of the polymer (Figure 3-2).  
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Figure 3-2: DSC Thermograms of Pure Clotrimazole (CTZ) and the CTZ/Soluplus
®
 
Physical Mixtures at Varying Drug Concentrations 
In the present research, drug was extruded with polymer alone at different concentrations, 
without utilizing any of the processing aids. During the extrusion process both of the recorded 
responses, torque and pressure, decreased with an increase in the drug concentration. The data 
presented in Table 3-1 could be attributed to the plasticization effect of CTZ on Soluplus
®
. 
Additionally, the 30% w/w CTZ-soluplus
®
 binary blends were subsequently exposed to barrel 
temperature for 1, 5, and 10 min, to further evaluate the effect of residence time. All of the 
produced extrudates exhibited very good post-processing drug content with a mean and relative 
standard deviation of 98.0% and 3.0%, respectively. 
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Table 3-1: Responses Observed During Melt Extrusion Processing of Clotrimazole at 
Different Drug Loads 
Drug Load Torque (N-cm) ∆P (bar) 
10% 72 37 
20% 60 16 
30% 37 8 
 
The DSC thermograms of the extrudates demonstrated drug miscibility up to 20% w/w, 
when processed for one minute at a barrel temperature of 130°C. The higher drug loads 
demonstrated a characteristic melting peak of the drug around 144°C (Figure 3-3). Interestingly, 
the drug’s melting peak disappeared in 30% w/w extrudates obtained by exposure at 130°C for 
10 minutes in comparison to those produced by 1 and 5 minutes exposure at the same 
temperature conditions (data not shown). As the time of drug exposure to heat increased, 
complete drug-polymer miscibility was observed at 30% w/w drug load.  
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Figure 3-3: DSC Thermograms of CTZ/Soluplus
®
 Hot Melt Extrudates: Effect of Drug 
Load 
 
FT-IR spectroscopic analysis was performed on the extruded samples to study the drug-
polymer interactions, and to corroborate the miscibility results obtained by DSC. The spectra of 
CTZ exhibit characteristic peaks at 3169 and 3042 cm
-1
 (aromatic C-H stretching), 1585, 1487 
and 1305 cm
-1
 (benzene ring stretching), 1203 cm
-1
 (C-N stretching), and 1084 cm
-1
 
(chlorobenzene stretching). The FTIR spectra of the extruded formulations presented in Table 3-
2 and Figure 3-4 demonstrate the presence of CTZ characteristic peaks, indicating the absence of 
any chemical interactions between the drug and the polymer. 
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Table 3-2: Characteristic Peaks in the FTIR Spectra of Clotrimazole (CTZ) in Different 
Hot Melt Extruded Formulations 
Formulations 
Aromatic C-H 
Stretching (3169 
& 3042 cm
-1
) 
Benzene ring 
Stretching (1585, 
1487 & 1305 cm
-
1
) 
C-N 
Stretching 
(1203 cm
-1
) 
Chlorobenzene 
(1084 cm
-1
) 
10% CTZ √ √ √ √ 
20% CTZ √ √ √ √ 
30% CTZ √ √ √ √ 
30% CTZ-5min √ √ √ √ 
30% CTZ-10min √ √ √ √ 
Note: “√” indicates presence of the characteristic peak 
Dissolution studies were conducted on the produced HME formulations to evaluate the 
enhanced drug release from the produced solid dispersions. Over 90% of CTZ was released in 
the first hour for the formulations containing 10% drug load. 10% CTZ-loaded matrices 
exhibited faster release followed by 20% and 30% w/w. This slower release could be attributed 
to the increasing concentration of hydrophobic drug from 10% to 30% in the extrudates. Drug 
load, however, did not have any significant impact on the release of formulations containing 10% 
and 20% CTZ (evident from ‘f2’ values presented in Table 3-3) since the crystalline CTZ was 
completely converted into an amorphous form in 10% and 20% drug loaded extrudates.  
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Figure 3-4: FTIR Spectra of Clotrimazole, Soluplus
®
, and Melt Extruded Formulations: 
(A) Effect of Drug Load; (B) Effect of Residence Time. The Colored Spectra are 
Represented as Follows: Black - Soluplus
®
; Blue – Clotrimazole (CTZ); Red – 10% CTZ 
HME; Green – 20% CTZ HME; Maroon – 30% CTZ-1min; Pink – 30% CTZ-5min; and 
Cyan – 30% CTZ-10min 
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Table 3-3: Comparison of Dissolution Profiles Utilizing Calculated ‘Similarity Factor’ 
Values Between Different Melt Extruded Formulations 
Formulations ‘f2
’
 factor 
Direct Flush - Drug Load Effect 
10%CTZ Vs 20%CTZ 56.1 
10%CTZ Vs 30%CTZ 31.2 
20%CTZ Vs 30%CTZ 39.2 
30% CTZ - Residence Time Effect 
CTZ 1min Vs CTZ 5 min 55.6 
CTZ 1min Vs CTZ 10 min 29.1 
CTZ 5min Vs CTZ 10 min 36.2 
 
Alternatively, the 30% drug loaded extrudates demonstrated a significantly slower release 
rate compared to 10% and 20% w/w drug loaded extrudates which can be attributed to the 
presence of crystalline drug in the higher drug loaded extrudates (Figure 3-5A). Moreover, the 
extrudates with 30% w/w drug load, when exposed at 130°C for 10 min in extrusion barrel did 
demonstrate a significantly faster release compared to the other formulations extruded after 1 and 
5 min exposure times at 130°C (Figure 3-5B). This is due to the formation of amorphous CTZ in 
the extrudates produced (data supported by DSC), when exposed to the set temperature for a 
longer duration (10 min). 
Stability is another important aspect of any formulation in the drug development cycle. In 
the current study, produced melt extruded formulations were subjected to both, physical (Figure 
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3-6A) and chemical stability (Figure 3-6B). The samples stored at three different temperatures 
were tested for crystallization of drug and found that the extruded formulations which formed 
amorphous dispersions initially have remained same and did not demonstrate any sign of re-
crystallization during the storage period of three months. Similarly, the drug content of the 
initially formed extrudates remained between 96-103% at the end of three months, indicating 
chemical stability of the drug. 
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Figure 3-5: Clotrimazole Release from Hot Melt Extruded Formulations: (A) Effect of 
Drug Load; (B) Effect of Residence Time. Data Represent Mean ± S.D (n=3) 
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Figure 3-6: (A) Physical Stability Obtained from DSC Thermograms and; (B) Chemical 
Stability Obtained Utilizing HPLC Analysis of the Clotrimazole-Soluplus
®
 Extrudates. 
Chemical Stability Data Represent Mean ± S.D (n=3) 
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3.4.Conclusion 
CTZ was found to be miscible in Soluplus
®
 up to 20% and 30% when processed for 1 min and 
10min, respectively. Both formulation and process parameters, namely drug load and residence 
time of the binary mixture had a significant impact on the drug-polymer miscibility in the final 
extrudates which was confirmed by DSC and FTIR Studies. In addition, both, the drug load and 
residence time also had a significant impact on the CTZ release from the melt extrudates. At a 
relatively lower drug loads, complete solubilization of CTZ in Soluplus
®
 was noticed. At the 
higher drug concentrations of CTZ (30% w/w drug load), an increase in the residence time of the 
formulation in the extrusion barrel aids in CTZ solubilization. The hydrophilic polymer, 
soluplus
®
, also combines the benefits of solid solutions and solubilization to further increase the 
dissolution rate of poorly soluble drugs. CTZ forms an amorphous solid dispersion within the 
soluplus
®
 matrix, and the melt extrudates containing up to 30% drug load were found to be 
physically and chemically stable for a period of 3 months. Moreover, soluplus
®
 was extrudable at 
90% w/w with only a model drug in the formulation. The characteristics associated with this 
relatively new polymer such as hydrophilicity and low glass transition temperature, along with 
its ease of extrusion and additional solubilization capacity (due to polyethylene glycol) makes it 
more appealing for utilization as a carrier matrix with myriad actives in HME processing. 
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CHAPTER - 4 
Characterization of Soluplus
®
 Hot Melt Extrudates: Effect of Formulation and Process 
Parameters on Miscibility, Dissolution and Stability Characteristics 
 
4.1. Introduction 
Curcumin is a safe, affordable and natural bioactive molecule of turmeric (Curcuma 
longa). It is a bright yellow colored natural product, practically insoluble in water at acidic and 
neutral pH, and soluble in alkali. This compound has gained considerable attention in recent 
years for its multiple pharmacological activities such as anti-inflammatory (49), anti-oxidant (50, 
51), anti-microbial (52), anti-cancer (53), anti-diabetic (54), and as a neuroprotective agent (55, 
56). In spite of its several potential therapeutic advantages, its optimum pharmaceutical potential 
has been limited by its lack of aqueous solubility and poor bioavailability (57, 58). To mitigate 
the above limitations research has been performed over the years to improve the solubility of 
curcumin utilizing nanocarriers, cyclodextrins (via complexation), carriers such as solutol
®
 HS
 
15 (via solid dispersions) and surfactants (via micellar solubilization) (59-63).  
Paradkar et al. has produced solid dispersion of curcumin and polyvinyl pyrrolidone 
utilizing spray drying technique (23). The authors demonstrated formation of a high energy 
amorphous phase and increased dissolution rate of curcumin from the produced solid dispersion 
when compared to their corresponding physical mixtures. In another study, Wu et al. utilized 
surfactants and appropriate solvents to produce self-microemulsifying drug delivery systems to 
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improve curcumin dissolution and bioavailability (64). Drug release from the formulation was 
completed within 10 minutes. The developed SMEDDS formulation improved the oral 
bioavailability of curcumin significantly, and the relative oral bioavailability of SMEDDS 
compared with curcumin suspension was 1213%. Recently, Bansal and co-workers produced 
curcumin implants using poly(ε-caprolactone) and HME technique (65). The data from the study 
showed that these implants were able to release curcumin for long duration and to modulate liver 
phase I and phase II enzymes, demonstrating curcumin’s biological efficacy delivered via this 
delivery system.  
Numerous research reports have been published on the use of hydrophilic polymers in 
producing solid dispersions to enhance dissolution rate of poorly soluble drugs. Soluplus
®
 is one 
of the novel polymers comprising of PEG 6000, vinylcaprolactam and vinyl acetate in the ratios 
of 13, 57, and 30, respectively. It is white yellowish free flowing granules with a glass transition 
temperature of 69°C. When extruded, it combines the benefits of both solubilization and 
formation of solid solutions to enhance the bioavailability of poorly soluble drugs (66). 
Surfactants, on the other hand, are also widely used solubilizing agents in many pharmaceutical 
dosage forms. These surfactants when used at appropriate levels form the micellar systems in 
which the poorly soluble drugs are encapsulated and form a more soluble system. In this study, 
we chose three different types of surfactants mainly classified based on their charge: cationic 
(Cetyltrimethyl ammonium bromide-CTAB), anionic (Sodium lauryl sulfate-SLS) and non-ionic 
(Pluronic
®
 F127) surfactants. Additionally, each of these surfactants was evaluated at three 
different concentrations to study their influence on drug release from the produced hot-melt 
extrudates. 
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Currently there are no available marketed formulations for curcumin as it exhibits 
solubility-limited poor oral bioavailability. In addition, there is no research reported utilizing 
combination of both, surfactants and HME. Therefore, in our current research, we attempted to 
formulate a solubilized curcumin oral dosage form with enhanced dissolution characteristics, and 
a high potential to demonstrate superior bioavailability utilizing a novel carrier, soluplus
®
, 
suitable surface active agents, and HME technology. The objective of this study was to 
investigate the feasibility of producing Soluplus
®
-Curcumin drug-loaded extrudates utilizing hot-
melt extrusion (HME) technology. In addition, drug-polymer miscibility studies, including the 
influence of charge and concentration of the utilized surfactants on dissolution rate of this poorly 
water-soluble model drug were also investigated.  
4.2. Materials & Methods  
4.2.1. Materials 
Curcumin, CTAB, SLS, and Pluronic
®
 F127 were purchased from Fisher Scientific (Fair 
Lawn, NJ, USA). Soluplus
®
 was kindly gifted by BASF Corporation. High performance liquid 
chromatography (HPLC) grade water was freshly prepared in the laboratory by Nanopure 
systems (Barnstead, Dubuque, IA, USA). All other solvents utilized in the study were of 
analytical grade and obtained from Fisher Scientific (Fair Lawn, NJ, USA). 
4.2.2. Analytical Method 
In-house reverse phase high performance liquid chromatography (HPLC) based 
analytical method was developed for determination/quantification of curcumin, and validated 
according to ICH and FDA guidelines for chromatographic method. An HPLC equipped with 
UV detector, Waters symmetry shield 5μ C18 column (250×4.6 mm), and an isocratic mode of 
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elution with mobile phase containing acetonitrile and 2% acetic acid solution in water (48:52) at 
a flow rate of 2.0 mL/min were employed to quantify the drug at a wavelength (λmax) of 425 
nm. The pH of the mobile phase is adjusted to 3.9, and the column temperature was maintained 
around 33°C. The acquired data was processed using Empower 2 build 2154 software (Waters 
Inc., Mount Holly, NJ, USA). 
4.2.3. Thermal Gravimetric Analysis (TGA) 
The thermal stability of the curcumin, and soluplus
® 
samples was determined as a 
function of weight loss. The analysis was performed on the samples (4-5 mg approximately) 
using a Perkin-Elmer Pyris 1 thermo-gravimetric analyzer (Norwalk, CT) operated at a ramp rate 
of 20°C/min from a temperature of 40°C to 250°C. The % weight loss for both the samples 
tested was recorded using the Pyris 1 TGA software. All of the TGA runs were performed in an 
open pan with purge and protective nitrogen gas flow at 40 mL/min. 
4.2.4. Differential Scanning Calorimetry (DSC) Analysis 
DSC was used to characterize the miscibility of curcumin in a polymeric carrier, 
soluplus
®
, utilizing a Perkin-Elmer Diamond DSC instrument (Shelton, CT). A 2-3 mg sample of 
the drug, polymer, and physical mixtures with varying drug concentrations (10, 20, 30, 40, and 
50%) were weighed and sealed in aluminum crimped pans (Kit 0219-0062, Perkin-Elmer 
Instruments, Shelton, CT). The physical mixture containing samples were subjected to an initial 
heat-cool cycle (by heating up to 230°C at the rate of 20°C/min, followed by immediate cooling) 
to remove the thermal history of the samples. A second heat cycle was initiated wherein the 
samples were reheated from 30 to 250°C at a ramp rate of 20°C/min under nitrogen purge at a 
flow rate of 20 mL/min. On the other hand, the melt extruded samples containing surfactants at 
 82 
varying concentrations were subjected to a single heating cycle from 30 to 250°C at a ramp rate 
of 20°C/min.  
4.2.5. Hot Melt Extrusion  
Curcumin and soluplus
®
 were used as a model drug and carrier matrix, respectively. Prior 
to processing, required materials previously sieved through mesh # 40 were accurately weighed 
and were further blended in a twin-shell dry V-blender (The Patterson-Kelly co., Inc. East 
Stroudsburg, PA) at a speed of 25rpm for 10 minutes. Each of the formulations contained 30% 
Curcumin (99% purity), Soluplus
®
 (60 – 67.5%), and a surfactant (SLS, CTAB, and/or Pluronic® 
F127), each at three different concentrations - 2.5%, 5%, and 10% w/w. These formulations were 
extruded utilizing a conical twin-screw compounder (MiniLab II HAAKE Rheomex CTW5, 
ThermoFisher Scientific) at 155°C and 70rpm screw speed. All of these final extrudates obtained 
were stored in foil-lined polyethylene bags and stored in a refrigerator until further analysis.  
4.2.5.1.Post-Processing Drug Content 
A portion of all of these extruded formulations were crushed into fine powder using 
mortar and pestle and stored in amber colored glass bottles. These processed and powdered 
extrudates were analyzed for the drug content immediately after extrusion through the hot melt 
extruder. A known amount (20 mg) of the extrudates and physical mixture were dissolved in 
100mL of acetonitrile and filtered using 0.2 µm, 13 mm PTFE membrane filters (Whatman, 
Piscataway, NJ) and analyzed utilizing a HPLC at a wavelength of 425 nm. 
4.2.6. Drug Release Testing 
Dissolution testing (USP XXXI, Apparatus II) was carried out utilizing a Hanson SR8-
plus™ dissolution test station (Hanson Research Corporation, Chatsworth, CA) operated at 75 
 83 
rpm paddle speed. The effect of surfactant type and concentration on drug release from 
extrudates containing 30% curcumin was studied. A sample weight containing curcumin 
equivalent to 100mg from each of the produced melt extruded formulations, previously ground in 
mortar and pestle, was accurately weighed and filled in gelatin capsule # 1. These capsules were 
added to the dissolution vessel containing 900mL of 0.5% w/w of SLS preheated to 37°C. 
During testing 1.5mL samples were removed from the dissolution vessels at pre-determined time 
intervals and replaced with an equal volume of fresh dissolution medium. The extruded 
formulation containing no surfactant, and the drug release from pure curcumin powder were 
utilized as controls. All of the samples were immediately filtered using 13 mm PTFE membrane 
filters (Whatman, Piscataway, NJ) with a pore size of 0.2 µm and analyzed using HPLC at a 
λmax of 425nm. Drug concentration was calculated from a standard calibration plot and 
expressed as cumulative % drug dissolved. The drug release from all of the melt extrudates and 
the pure drug were compared. The release studies were performed in triplicate and the mean 
values were compared. 
4.3. Results & Discussion 
The TGA studies (data not shown) revealed that Soluplus
®
 and Curcumin were stable 
under employed extrusion temperatures. Hence, the formulations under study were extruded 
utilizing a conical twin-screw compounder (MiniLab II HAAKE Rheomex CTW5, 
ThermoFisher Scientific) at 155°C and 70rpm screw speed. Each of the formulations contained 
30% curcumin (99% purity), soluplus
®
 (60 – 67.5%), and a surfactant (SLS, CTAB, and/or 
Pluronic
®
 F127), each at three different concentrations - 2.5%, 5%, and 10% w/w. The post-
processing content results are presented in Figure 4-1. All of the produced formulations under 
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employed extrusion conditions exhibited a higher post-processing drug content (97-100%) with 
tighter standard deviation (<3%), indicating a robust formulation and process.  
 
Figure 4-1: Post-Processing Drug Content of Curcumin Melt Extrudates 
 
The DSC studies revealed that Curcumin exhibited an onset of melting endotherm at 
around 172°C. The drug’s melting peak was visible in the physical mixtures (up to 50% w/w of 
drug) during the first heating cycle (Figure 4-2A), which disappeared following the second 
heating cycle. However, all of the produced extrudates did not demonstrate any melting 
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endotherm corresponding to curcumin, polymer, and/or the surfactants employed even during the 
first heating cycle. The thermograms of all of the extruded formulations (Figures 4-2B to 4-2D) 
demonstrated a single phase system, indicating an excellent miscibility of 30% Curcumin in the 
Soluplus
®
 matrix. 
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Figure 4-2: Curcumin-Soluplus
®
 Miscibility Studies – (A) Comparative Study of the Drug-
Polymer Physical Mixtures with Increased Drug Loading; (B) SLS HME Formulations 
with 30% Curcumin; (C) CTAB HME Formulations with 30% Curcumin; and (D) 
Pluronic
®
 F127 HME Formulations with 30% Curcumin 
 
It is also anticipated that the formed high-energy amorphous systems during extrusion 
would enhance the drug release from the extrudates. However, the impact of utilized surfactants 
in the formulation on the release of curcumin was not clearly understood. Therefore, drug release 
profiles obtained from all of the melt extrudates and the pure drug were compared. The 
interaction of curcumin with various charged aqueous surfactant solutions showed it exists in 
deprotonated enol form in surfactant solutions. The nitro and hydroxyl groups of o-nitrophenol 
interact with the carbonyl and hydroxyl groups of the enol form of curcumin by forming ground 
state complex through hydrogen bonds and offered interesting information about the nature of 
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the interactions between the aqueous surfactant solutions and curcumin depending on charge of 
head group of the surfactant. 
All of the extrudates released significantly higher amounts of curcumin (~64-100%) 
compared to that of the pure drug (~20%). Moreover, effect of charged surfactants and their 
concentrations on the release of curcumin was predominant. Increase in the SLS concentration 
from 2.5% to 10% decreased the drug release from 95.4% to 54.5% after 60 minutes (Figure 4-
3A). This decrease in drug release could be attributed to the hydrolytic degradation of Curcumin 
in the alkaline pH (8.5-9.0) of dissolution medium (67). It has been reported that the Curcumin 
undergoes deprotonation in alkaline pH and exists as a negatively charged molecule (Cur
3-
). The 
SLS micelles cannot prevent the degradation of the compound due to the electrostatic repulsions 
between the negatively charged head groups and Cur
3-
, resulting in the dissociation of Cur
3- 
from 
the micelle followed by its alkaline hydrolysis in the aqueous phase of the solution (68).  
On the contrary, increased drug release was noticed with increasing concentration of 
CTAB from 2.5% to 10% (Figure 4-3B). This could be attributed to the improved stability of 
Curcumin due to its interaction with CTAB molecules. The cationic surfactants stabilize 
deprotonated Curcumin, Cur
3-
, due to the attractive electrostatic interactions between the ionized 
drug and the positively charged CTAB head groups. No significant improvement in the drug 
dissolution was observed with increasing concentrations of non-ionic surfactant, Pluronic F127, 
when compared to the control formulation containing no surfactant, but only curcumin and 
soluplus
® 
(Figure 4-3C).  
All of these formulations were stored in accelerated conditions (40°C/75% RH) to study 
their physical stability. These stored formulations were subjected to DSC analysis at the end of 
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three months period and none of them exhibited recrystallization of curcumin in the extrudates 
(data not presented), demonstrating the physical stability of the formulations. 
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Figure 4-3: Effect of Surfactant Concentrations on Curcumin Dissolution from Hot-Melt 
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Extrudates – (A) SLS; (B) CTAB; (C) Pluronic F127 
4.4. Conclusions 
Curcumin was found to be miscible in soluplus
®
 up to 50% drug load. Both, charge and 
the concentration of surfactant had a significant impact on the drug release from the HME 
extrudates. HME has been successfully utilized in conjunction with Soluplus
®
, and other 
functional excipients to improve the physical stability and the drug release. Soluplus
®
 may 
provide a solution to increase solubility of poorly soluble drugs. 
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CHAPTER - 5 
Summary and Conclusions 
5.1.   Hot Melt Extrusion: A Promising Technique to Produce a Novel Abuse-Deterrent 
Formulation  
 HME was demonstrated as a viable technique with a potential to develop novel abuse-
deterrent formulations  
 PEO 301 demonstrated its utility as a feasible TR matrix 
 HPMC K15M in combination with CBP significantly improved the gelling characteristics 
in water and alcohol 
 The optimized response models created for ‘%API extracted in water’ and ‘% API 
extracted in alcohol’ also correlated well with the data generated, validating the 
developed model.  
5.2.   Characterization of Kollidon
®
 VA 64 Hot Melt Extrudates: Influence of Formulation 
and Process Parameters on Dissolution and Stability Characteristics 
 Kollidon VA® 64 was extrudable at 75% w/w with only a model drug in the formulation. 
 Both of the processing parameters, temperature and screw speed, had a significant impact 
on the post-processing drug content of the final extrudates. 
 NIF forms a stable amorphous solid dispersion in Kollidon VA® 64 matrix. 
 Drug release from all of the hot melt extrudates produced was similar. Moreover, release 
from the extrudates was found to be superior compared to the physical mixtures. 
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 NIF was found to be physically and chemically stable throughout the study period.  
5.3. Characterization of Soluplus
®
 Hot Melt Extrudates: Effect of Formulation and Process 
Parameters on Miscibility, Dissolution and Stability Characteristics 
 At 10% and 20% drug load, there is complete solubilization of CTZ in Soluplus®. 
However, at higher drug loading of CTZ (30% drug load), the increase in residence time 
of the formulation in the extrusion barrel helps aid solubilization of CTZ.  
 Drug load and heat exposure/residence time had a significant impact on the drug-polymer 
miscibility in the final extrudates, which was confirmed by DSC and FTIR Studies. 
 Both, the drug load and residence time had a significant impact on the CTZ release from 
the melt extrudates. 
 CTZ forms an amorphous solid dispersion within the Soluplus® matrix, and the melt 
extrudates containing up to 30% drug load were found to be physically and chemically 
stable for a period of 3 months. 
 Moreover, Soluplus® was extrudable at 90% w/w with only a model drug in the 
formulation. 
  Soluplus® combines the benefits of solid solutions and solubilization which thereby 
increases solubility of poorly soluble drugs. 
5.4. Influence of Hot Melt Extrusion Technology, and Effect of Type and Concentration of 
Surfactants on Miscibility and Drug Release from Soluplus
®
-Curcumin Mixtures 
 HME has been successfully utilized in conjunction with Soluplus®, and other functional 
excipients to improve the physical stability and the drug release 
 Curcumin formed a single phase miscible system in soluplus® up to 50% drug load.  
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 Both, charge and the concentration of surfactant had a significant impact on the drug 
release from the HME extrudates. 
 Extrudates were found to be physically stable throughout the storage period of three 
months under accelerated storage conditions. 
 Soluplus®, in combination with appropriate surfactants may provide a solution to increase 
solubility and stability of the poorly soluble drugs. 
 
 
 
 
 
  
 95 
 
 
 
 
 
 
 
BIBLIOGRAPHY  
 96 
1. Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent 
formulations. Drug Dev Ind Pharm2012 Apr 26. 
2. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities 
and complications of the escalating use, abuse, and nonmedical use of opioids. Pain 
Physician2008 Mar;11(2 Suppl):S63-88. 
3. Boyd CJ, McCabe SE, Cranford JA, Young A. Prescription drug abuse and diversion 
among adolescents in a southeast Michigan school district. Arch Pediatr Adolesc Med2007 
Mar;161(3):276-81. 
4. Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of 
administration of different prescription opioid compounds and formulations. Harm Reduct 
J;8:29. 
5. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et al. Patterns of abuse 
among unintentional pharmaceutical overdose fatalities. JAMA2008 Dec 10;300(22):2613-20. 
6. Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving 
pseudoscience on the Internet. Drug Alcohol Depend2006 Jun;83 Suppl 1:S31-9. 
7. Sloan P, Babul N. Extended-release opioids for the management of chronic non-
malignant pain. Expert Opin Drug Deliv2006 Jul;3(4):489-97. 
8. Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of 
prescription drug abusers entering drug rehabilitation. J Pain Palliat Care 
Pharmacother2006;20(2):5-13. 
9. Meng Y, Lichtman AH, Bridgen DT, Martin BR. Inhalation studies with drugs of abuse. 
NIDA Res Monogr1997;173:201-24. 
 97 
10. Hays LR. A profile of OxyContin addiction. J Addict Dis2004;23(4):1-9. 
11. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid 
formulations. Pain Med2009 Jul;10 Suppl 2:S124-33. 
12. Bartholomaeus JH, Arkenau-Maric E, Galia E. Opioid extended-release tablets with 
improved tamper-resistant properties. Expert Opin Drug Deliv Aug;9(8):879-91. 
13. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F, et al. 
Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev Ind Pharm2007 
Oct;33(10):1043-57. 
14. Repka MA, Majumdar S, Kumar Battu S, Srirangam R, Upadhye SB. Applications of 
hot-melt extrusion for drug delivery. Expert Opin Drug Deliv2008 Dec;5(12):1357-76. 
15. Palem CR, Kumar Battu S, Maddineni S, Gannu R, Repka MA, Yamsani MR. Oral 
transmucosal delivery of domperidone from immediate release films produced via hot-melt 
extrusion technology. Pharm Dev Technol Aug 13. 
16. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK, et al. 
Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm2007 
Sep;33(9):909-26. 
17. Repka MA, Shah S, Lu J, Maddineni S, Morott J, Patwardhan K, et al. Melt extrusion: 
process to product. Expert Opin Drug Deliv Jan;9(1):105-25. 
18. Keldmann T. Advanced simplification of nasal delivery technology: anatomy + 
innovative device = added value opportunity, in Nasal Drug Delivery: Rapid Onset via 
Convenient Route. ONdrugDelivery. 2005:4-7. 
19. D. Palmer, M. Levina, T. P. Farrell, Rajabi-Siahboomi AR. The influence of hydro-
 98 
alcoholic media on drug release from polyethylene oxide extended-release matrix tablets. 
PharmTech2011;35(7):50-8. 
20. A. S. Apu, A. H. Pathan, G. Kibria, Jalil R. In vitro Release Kinetic Study of 
Theophylline from Eudragit RS PO and Eudragit RL PO Matrix Tablets, Dhaka Univ J Pharm 
Sci 2009;8(1):1-6. 
21. S. B. Tiwari, Rajabi-Siahboomi AR. Modulation of drug release from hydrophilic 
matrices. PharmTech Eur2008(September):1-8. 
22. Roberts M, Cespi M, Ford JL, Dyas AM, Downing J, Martini LG, et al. Influence of 
ethanol on aspirin release from hypromellose matrices. International Journal of 
Pharmaceutics2007;332(1â€“2):31-7. 
23. Paradkar A, Ambike AA, Jadhav BK, Mahadik KR. Characterization of curcumin-PVP 
solid dispersion obtained by spray drying. Int J Pharm2004 Mar 1;271(1-2):281-6. 
24. Arora SC, Sharma PK, Irchhaiya R, Khatkar A, Singh N, Gagoria J. Development, 
characterization and solubility study of solid dispersions of azithromycin dihydrate by solvent 
evaporation method. J Adv Pharm Technol Res Apr;1(2):221-8. 
25. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of 
nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm2005 Aug 
11;299(1-2):167-77. 
26. Battu SK, Repka MA, Maddineni S, Chittiboyina AG, Avery MA, Majumdar S. 
Physicochemical characterization of berberine chloride: a perspective in the development of a 
solution dosage form for oral delivery. AAPS PharmSciTech Sep;11(3):1466-75. 
27. Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by 
 99 
micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur J 
Pharm Biopharm2008 Feb;68(2):283-8. 
28. Shibata Y, Fujii M, Sugamura Y, Yoshikawa R, Fujimoto S, Nakanishi S, et al. The 
preparation of a solid dispersion powder of indomethacin with crospovidone using a twin-screw 
extruder or kneader. Int J Pharm2009 Jan 5;365(1-2):53-60. 
29. Verhoeven E, De Beer TR, Van den Mooter G, Remon JP, Vervaet C. Influence of 
formulation and process parameters on the release characteristics of ethylcellulose sustained-
release mini-matrices produced by hot-melt extrusion. Eur J Pharm Biopharm2008 
May;69(1):312-9. 
30. Nakamichi K, Nakano T, Yasuura H, Izumi S, Kawashima Y. The role of the kneading 
paddle and the effects of screw revolution speed and water content on the preparation of solid 
dispersions using a twin-screw extruder. Int J Pharm2002 Jul 25;241(2):203-11. 
31. Dinunzio JC, Schilling SU, Coney AW, Hughey JR, Kaneko N, McGinity JW. Use of 
highly compressible Ceolus microcrystalline cellulose for improved dosage form properties 
containing a hydrophilic solid dispersion. Drug Dev Ind Pharm Feb;38(2):180-9. 
32. Jijun F, Lishuang X, Xiaoli W, Shu Z, Xiaoguang T, Xingna Z, et al. Nimodipine (NM) 
tablets with high dissolution containing NM solid dispersions prepared by hot-melt extrusion. 
Drug Dev Ind Pharm Aug;37(8):934-44. 
33. Hancock BC, York P, Rowe RC. The use of solubility parameters in pharmaceutical 
dosage form design. International Journal of Pharmaceutics1997;148(1):1-21. 
34. Forster A, Hempenstall J, Tucker I, Rades T. Selection of excipients for melt extrusion 
with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int 
 100 
J Pharm2001 Sep 11;226(1-2):147-61. 
35. Greenhalgh DJ, Williams AC, Timmins P, York P. Solubility parameters as predictors of 
miscibility in solid dispersions. J Pharm Sci1999 Nov;88(11):1182-90. 
36. Caira MR, Robbertse Y, Bergh JJ, Song M, De Villiers MM. Structural characterization, 
physicochemical properties, and thermal stability of three crystal forms of nifedipine. J Pharm 
Sci2003 Dec;92(12):2519-33. 
37. Chutimaworapan S, Ritthidej GC, Yonemochi E, Oguchi T, Yamamoto K. Effect of 
water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Dev Ind 
Pharm2000 Nov;26(11):1141-50. 
38. Fukuda M, Miller DA, Peppas NA, McGinity JW. Influence of sulfobutyl ether beta-
cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates 
prepared by hot-melt extrusion. Int J Pharm2008 Feb 28;350(1-2):188-96. 
39. Battu SK, Repka MA, Majumdar S, Madhusudan RY. Formulation and evaluation of 
rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm2007 
Nov;33(11):1225-32. 
40. Zolnik BS, Leary PE, Burgess DJ. Elevated temperature accelerated release testing of 
PLGA microspheres. J Control Release2006 May 30;112(3):293-300. 
41. Lust A, Laidmae I, Palo M, Meos A, Aaltonen J, Veski P, et al. Solid-state dependent 
dissolution and oral bioavailability of piroxicam in rats. Eur J Pharm Sci Oct 22. 
42. Kalivoda A, Fischbach M, Kleinebudde P. Application of mixtures of polymeric carriers 
for dissolution enhancement of fenofibrate using hot-melt extrusion. Int J Pharm Jun 15;429(1-
2):58-68. 
 101 
43. Maniruzzaman M, Rana MM, Boateng JS, Mitchell JC, Douroumis D. Dissolution 
enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic 
polymers. Drug Dev Ind Pharm Mar 28. 
44. Thakral NK, Ray AR, Bar-Shalom D, Eriksson AH, Majumdar DK. Soluplus--solubilized 
citrated camptothecin--a potential drug delivery strategy in colon cancer. AAPS PharmSciTech 
Mar;13(1):59-66. 
45. Pokharkar VB, Malhi T, Mandpe L. Bicalutamide nanocrystals with improved oral 
bioavailability: in vitro and in vivo evaluation. Pharm Dev Technol Mar 7. 
46. Liu X, Lu M, Guo Z, Huang L, Feng X, Wu C. Improving the chemical stability of 
amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm Res 
Mar;29(3):806-17. 
47. Hughey JR, Keen JM, Brough C, Saeger S, McGinity JW. Thermal processing of a 
poorly water-soluble drug substance exhibiting a high melting point: the utility of KinetiSol(R) 
Dispersing. Int J Pharm Oct 31;419(1-2):222-30. 
48. Nagy ZK, Balogh A, Vajna B, Farkas A, Patyi G, Kramarics A, et al. Comparison of 
electrospun and extruded Soluplus(R)-based solid dosage forms of improved dissolution. J 
Pharm Sci Jan;101(1):322-32. 
49. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of 
tumeric (Curcuma longa). J Altern Complement Med2003 Feb;9(1):161-8. 
50. Motterlini R, Foresti R, Bassi R, Green CJ. Curcumin, an antioxidant and anti-
inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative 
stress. Free Radic Biol Med2000 Apr 15;28(8):1303-12. 
 102 
51. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv 
Exp Med Biol2007;595:105-25. 
52. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, et al. 
Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during 
infections in mice. Antimicrob Agents Chemother2009 Apr;53(4):1592-7. 
53. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and 
clinical studies. Anticancer Res2003 Jan-Feb;23(1A):363-98. 
54. Abdel Aziz MT, El-Asmar MF, El-Ibrashy IN, Rezq AM, Al-Malki AL, Wassef MA, et 
al. Effect of novel water soluble curcumin derivative on experimental type- 1 diabetes mellitus 
(short term study). Diabetol Metab Syndr2012;4(1):30. 
55. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med 
Biol2007;595:197-212. 
56. Lee HS, Jung KK, Cho JY, Rhee MH, Hong S, Kwon M, et al. Neuroprotective effect of 
curcumin is mainly mediated by blockade of microglial cell activation. Pharmazie2007 
Dec;62(12):937-42. 
57. Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic 
opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. 
Springerplus Dec;2(1):56. 
58. Zhang J, Tang Q, Xu X, Li N. Development and evaluation of a novel phytosome-loaded 
chitosan microsphere system for curcumin delivery. Int J Pharm Mar 19;448(1):168-74. 
59. Mohanty C, Das M, Sahoo SK. Emerging role of nanocarriers to increase the solubility 
and bioavailability of curcumin. Expert Opin Drug Deliv2012 Nov;9(11):1347-64. 
 103 
60. Rocks N, Bekaert S, Coia I, Paulissen G, Gueders M, Evrard B, et al. Curcumin-
cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung 
cancer. Br J Cancer2012 Sep 25;107(7):1083-92. 
61. Hegge AB, Masson M, Kristensen S, Tonnesen HH. Investigation of curcumin-
cyclodextrin inclusion complexation in aqueous solutions containing various alcoholic co-
solvents and alginates using an UV-VIS titration method. Studies of curcumin and 
curcuminoides, XXXV. Pharmazie2009 Jun;64(6):382-9. 
62. Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK. Curcumin-encapsulated 
MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer 
therapy. Nanomedicine (Lond)2010 Apr;5(3):433-49. 
63. Patra D, Barakat C. Unique role of ionic liquid [bmin][BF4] during curcumin-surfactant 
association and micellization of cationic, anionic and non-ionic surfactant solutions. Spectrochim 
Acta A Mol Biomol Spectrosc2011 Sep;79(5):1823-8. 
64. Wu X, Xu J, Huang X, Wen C. Self-microemulsifying drug delivery system improves 
curcumin dissolution and bioavailability. Drug Dev Ind Pharm2011 Jan;37(1):15-23. 
65. Bansal SS, Vadhanam MV, Gupta RC. Development and in vitro-in vivo evaluation of 
polymeric implants for continuous systemic delivery of curcumin. Pharm Res May;28(5):1121-
30. 
66. Djuris J, Nikolakakis I, Ibric S, Djuric Z, Kachrimanis K. Preparation of carbamazepine-
Soluplus(R) solid dispersions by hot-melt extrusion, and prediction of drug-polymer miscibility 
by thermodynamic model fitting. Eur J Pharm Biopharm2013 Jan 18. 
67. Leung MH, Colangelo H, Kee TW. Encapsulation of curcumin in cationic micelles 
 104 
suppresses alkaline hydrolysis. Langmuir2008 Jun 3;24(11):5672-5. 
68. Wang Z, Leung MH, Kee TW, English DS. The role of charge in the surfactant-assisted 
stabilization of the natural product curcumin. Langmuir2010 Apr 20;26(8):5520-6. 
 
 
 
 105 
VITA 
 
Sindhuri Maddineni, proud daughter of Mrs. Sandhya Maddineni and Mr. Krishnaiah 
Maddineni, was born in Andhra Pradesh, India on October 9, 1986. She attended Goutham 
Junior college in Vijayawada and she excelled in the state level competitive examination to get 
an entry in to one of the top universities of the state, University College of Pharmaceutical 
Sciences, Kakatiya University, India to pursue her Bachelors in Pharmacy.  She graduated with a 
first class distinction in November 2007.  
Immediately after completion of her Bachelors Program, she joined The University of 
Mississippi to earn her Doctoral Degree in Pharmaceutics. While continuing her education at the 
University of Mississippi, she also completed her internship in 2011at Abbott Pharmaceuticals 
(Waukegan, IL). Sindhuri gained vast knowledge in pre-formulation aspects of solid dosage 
forms, including the powder flow characterization by developing a predictive mathematical 
model during her internship. 
Sindhu is a member of Honor Societies of Phi Kappa Phi, Sigma Xi, and Rho-Chi 
National Scholars Honorary Society. She is also a recipient of several awards including 
“Graduate Dissertation Fellowship” (University of Mississippi-2011), “Center of Research 
Excellence in Natural Products Neuroscience Fellowship” (funded by NIH for the year 2010 -
2011), “Graduate Travel Award” (Kakatiya University UCPS Alumni Association-USA chapter-
2010 & 2011 ) and “Best Poster Presentation Award” (Southern Regional Discussion Group 
 106 
(SRDG, Memphis–2011). As a graduate student, she served as the Senator for the Department of 
Pharmaceutics in Graduate Student Council (2010-2011), and Secretary (2010-2011) for the 
AAPS-University of Mississippi Student Chapter. She also served as a Graduate Teaching 
Assistant for Physical Pharmacy and Basic Pharmaceutics course (August 2008 – December 
2009). Sindhu received the Doctor of Philosophy degree in Pharmaceutics in April 2013. 
 
 
 
 
